Advanced azelaic acid hyalubilosome-loaded microneedles for potent anti-inflammatory, antioxidant, and antimicrobial for Acne treatment by up-regulation of Nrf2/HO-1 signaling pathway Authors: Sammar Fathy Elhabal, Mohamed Fathi Mohamed Elrefai, Fatma E Hassan, Nahla Sameh Tolba, Rania Mostafa Abd El Galil, Suzan Awad AbdelGhany Morsy, Shady Allam, Amr M Emam, Hanaa Wanas, Marian Sobhy Azer, Mona Mohamed Ahmed, Hoda Ahmed Abdelmoneim, Marwa Fady, Ahmed Mohsen Elsaid Hamdan Published: 2026 ABSTRACT AbstractAcne vulgaris is a multifactorial inflammatory skin disorder in which the clinical utility of azelaic acid (AZA) is limited by poor aqueous solubility and inadequate skin permeation. This study developed AZA-loaded hyalubilosomes (AZA-HBs) integrated into dissolving PVA/PVP-chitosan microneedles (MNs) to improve dermal delivery and anti-acne efficacy. AZA-HBs formulations were developed using Design-Expert® software to study the effects of hyaluronic acid and bile salt amount, optimized via I-optimal design, and incorporated into dissolving MNs. The optimized AZA-HBs showed high entrapment efficiency (87.0 ± 0.55%), nanosized vesicles (170 ± 0.72 nm), narrow dispersity (PDI 0.33 ± 0.01), and good colloidal stability (zeta potential −29 ± 0.28 mV). The selected MN formulation exhibited excellent drug loading (95.3 ± 1.2%), strong mechanical performance with only (11.0 ± 1.0%) height reduction, and efficient insertion. The hybrid platform provided sustained AZA release, reaching (94–95%) over 48 h, and increased ex vivo skin permeation by (6.3-fold). It also improved cytocompatibility in HaCaT cells, whereas free AZA caused complete cell loss at the highest tested concentration. Moreover, the formulation enhanced antimicrobial potency (MICs of 6.25 μg/mL against S. epidermidis and 12.5 μg/mL against S. aureus) and eradicated (78%) of the biofilm. In vivo, AZA-HBs/MNs produced the strongest anti-acne effect, markedly reducing ear inflammation, suppressing TNF-α, IL-1β, IL-6, and TLR4, modulating Nrf2/HO-1/MYD88 signaling, and restoring normal histological and EGF immunohistochemical features. AZA-HBs-loaded dissolving PVA/PVP-chitosan microneedles offer sustained release, superior penetration, strong antimicrobial/antibiofilm activity, and significant anti-acne efficacy for topical AZA delivery.Keywords: Azelaic acid, Hyaluronic acid, Microneedles, Acne vulgaris, Antibiofilm, Antimicrobial, Antioxidant Introduction Acne vulgaris (AV) is a common chronic inflammatory condition affecting the pilosebaceous unit. Comedones, papules, pustules, nodules, and scarring are the clinical features of this condition (Elhabal et al., 2024; Kwon et al., 2017). Its pathophysiology includes excessive sebum production, follicular hyperkeratinization, microbial colonization, and the activation of local inflammatory responses (Jain et al., 2016; Li et al., 2025). Aside from its cutaneous manifestations, acne can significantly influence quality of life and is usually connected with psychological suffering, such as anxiety, sadness, and low self-esteem (Tolentino et al., 2021; Zhang et al., 2025a). Non-inflammatory comedones and inflammatory pustules, papules, and nodules are manifestations of the condition. Acne is characterized by the presence of comedones and pustules (H. Fan et al., 2025a; Zhang et al., 2025b). The selective disposition, bioavailability, and permeation enhancement of the topical acne and concomitant scalp conditions, and selective, targeted hair follicles. Systemic treatments can be used as adjuncts or alternatives to topical therapy (Blaskovich et al., 2019; Kansom et al., 2025). Topical retinoids, benzoyl peroxide, antibiotics, antiandrogens, and systemic treatments are all used to treat moderate-to-severe acne. Although these treatments are commonly utilized, their therapeutic efficacy may be restricted due to discomfort, dryness, poor patient adherence, recurrence, and safety issues associated with long-term or systemic administration. Long-term usage of topical and systemic antibiotics, in particular, has contributed to rising antimicrobial resistance concerns. There is still a need for targeted, non-antibiotic, and better-tolerated treatment techniques that can simultaneously target inflammation, microbial development, oxidative stress, and aberrant follicular keratinization. Most of the first-line treatments include topical antibiotics (e.g., clindamycin, erythromycin, clarithromycin, azithromycin, and nadifloxacin), antiandrogens (e.g., cyproterone acetate), and retinoids (e.g., tretinoin, adaplene, tazarotene, isotretinoin, and metretinide) (Elhabal et al., 2024; Yang et al., 2026). The use of antibiotics in acne vulgaris treatment is complicated by the development of bacterial resistance and the persistence of side effects (Rottboell et al., 2015; Wang et al., 2013). Azelaic acid (AZA), is a natural dicarboxylic acid synthesized by Malassezia furfur, with competitive anti-bacterial (C. acnes), anti-inflammatory, and keratolytic properties (Arshad et al., 2024; Nautiyal and Wairkar, 2023). AZA was chosen for this investigation because it directly targets several important pathogenic components of acne. AZA is a naturally occurring dicarboxylic acid with antibacterial, anti-inflammatory, antioxidant, anti-keratinizing, and tyrosinase inhibitory properties. The topical AZA treatment has a half-life of approximately 12 h and, in most cases, requires the patient to apply it to the affected areas at least twice a day (Jacobus Berlitz et al., 2019). These combined effects make AZA very effective in acne lesions characterized by inflammation and post-inflammatory hyperpigmentation. Unlike antibiotic-based therapy, AZA does not rely solely on conventional antibiotic mechanisms, making it an appealing option for lowering reliance on topical antibiotics in long-term acne control. The anti-inflammatory activity of AZA has been associated with the inhibition of proinflammatory cytokine release, down-regulation of cathelicidins, and inhibition of reactive oxygen species (ROS) production by granulocytes during the inflammatory response (Nazzaro-Porro et al., 1980; Pathak et al., 1985). AZA has no keratinization, follicular, or hyperkeratinization, and reduces the excessive stratum corneum thickness, decreases the keratohyalin granules, decreases the distribution and amount of filaggrin, reduces cell proliferation, and is a competitive inhibitor of all important/inclusion vital mitochondrial respiratory enzymes, that is, NADH dehydrogenase, succinic dehydrogenase, and ubiquinone oxidase (Lowe et al., 1998). Inhibition of melatonin generation is also a consequence of inhibition of tyrosinase-like enzymes, leading to a loss of melanin and melanosomes (Thiboutot et al., 2003; Wang et al., 2021). However, AZA's belonging to BCS II have low solubility in water (approximately 0.24 g/100 g of water at 25 OC) and their limited penetration into the skin limits their use. Therefore, a significant increase in the formulation to 10% w/w or 20% w/w is needed to achieve the desired therapeutic effect (Fitton and Goa, 1991; Picardo et al., 1985). This, however, is constrained by dose-dependent side effects such as erythema, burning, stinging and tingling, dryness, scaling, and peeling, and therefore necessitates the development of a new approach to deliver the formulation most effectively (Schallreuter and Wood, 1990). Hyaluobilosomes (HBs) or Hyaluronic acid gel-filled core bilosomes have been previously studied (Abd El Hady et al., 2025) as novel liposomes that consist of phospholipid vesicles encapsulating gel material in their core (Kawar and Abdelkader, 2019). Hyalubilosomes are a promising vesicular delivery strategy because they combine the penetration-enhancing properties of bile-salt-containing vesicles with the hydration and bioadhesion properties of hyaluronic acid (Othman et al., 2025). Several topical AZA administration methods have previously been studied to overcome its low water solubility and limited skin absorption. These include standard creams and gels, ethosomal systems, liposomal or lipogel formulations, nanostructured lipid carriers, hydrogels, and micro- and nanocrystal-based systems (Malik and Kaur, 2018; Mistry et al., 2016). These experiments found that nanocarrier-based solutions outperformed conventional topical formulations in terms of AZA deposition, skin targeting, antibacterial efficacy, and sustained release (Burchacka et al., 2016). However, most of these techniques still rely on passive diffusion through the stratum corneum, which may limit AZA deposition into the deeper epidermal and follicular compartments important in acne etiology (El-Nawawy et al., 2024; El-Refaie et al., 2015). The bilosomal core structures serve as drug containment while sustaining drug release. The bilosomal design of HBs is relevant to the treatment of acne, post-inflammatory hyperpigmentation, and other skin disorders, as the therapeutic system is designed to act locally in the dermis, unlike traditional delivery systems. Additionally, for AZA, the bilosomal design helps reduce patient irritation while targeting epidermal follicles and increasing the drug's therapeutic effect on the skin lesion (Kharouba et al., 2022). Microneedles are microstructured delivery methods that form temporary aqueous microchannels across the stratum corneum while avoiding deeper pain receptors and blood vessels. Dissolving microneedles are particularly desirable for dermatological administration because they are made of biocompatible and water-soluble polymers that dissolve after insertion, releasing the loaded medication or nanocarrier directly into the skin. Microneedles can improve local drug deposition, bypass the stratum corneum barrier, reduce systemic exposure, and improve patient acceptability compared to conventional injections. Incorporating AZA-HBs into dissolving microneedles was anticipated to increase intradermal AZA availability, lengthen local residency time, and boost anti-inflammatory, antibacterial, antioxidant, and antibiofilm actions at the diseased site. Chitosan, polyvinyl alcohol (PVA), and polyvinyl pyrrolidone (PVP) are the most common biopolymers used in the construction of a microneedle system, due to their biocompatibility and ability to form a drug delivery matrix that enables durable, controlled drug release or rapid drug release (Elhabal et al., 2026a, Elhabal et al., 2025a). This ability is especially true for chitosan, which is due to its pronounced film-forming capabilities, as well as its biodegradability and skin-adherent properties. PVA and PVP improve the biopolymer matrix by increasing mechanical strength, solubility, and the ability to form microneedles (Elhabal et al., 2026e). In microneedle designs, integrating chitosan with PVA or PVP can optimize mechanical strength and dissolution rate. Strong microneedles capable of penetrating the skin have been developed using chitosan/PVP and chitosan/PVA (Elhabal et al., 2025c; Stoeva et al., 2025). PVP facilitates more sustained drug release and PVA aids in structural stability and quick dissolution. These properties render chitosan-PVA-PVP microneedles suitable for the transdermal delivery of poorly permeable, low-bioavailability drugs (Fathy Elhabal et al., 2026b). This microneedle platform is particularly beneficial for azelaic acid, as it can penetrate the stratum corneum, enhance localized delivery, minimize irritation, and improve targeting to the skin layers involved in the acne-related inflammatory process (Fathy Elhabal et al., 2025). From a formulation perspective, chitosan/PVA/PVP microneedles can be utilized as the ultimate delivery patch for azelaic acid-encapsulated nanocarriers, such as HBs or bilosomes (Elhabal et al., 2025e).In the proposed dosage form, AZA is the primary active pharmaceutical ingredient responsible for the anti-acne therapeutic activity. It inhibits tyrosinase, which helps restrict the development of acne-associated bacteria, reduce the generation of inflammatory mediators, limit oxidative stress, regulate aberrant keratinization, and alleviate post-inflammatory hyperpigmentation. The hyalubilosome vesicles and PVA/PVP-chitosan microneedle matrix, on the other hand, are primarily delivery-enhancing components, intended to improve AZA loading, protect the drug within the formulation, facilitate penetration across the stratum corneum, sustain local release, and increase drug availability at the inflamed pilosebaceous target site. In the current study, the novelty of the present work lies in developing a hybrid delivery platform that integrates AZA-loaded hyalubilosomes with dissolving PVA/PVP-chitosan microneedles to penetrate the stratum corneum barrier and promote localized intradermal deposition. This hybrid approach is intended to promote AZA retention, offer prolonged release, improve skin permeability, and boost therapeutic efficacy against acne-related inflammation, oxidative stress, microbial colonization, and biofilm formation. The goal of this work was to create and optimize AZA-loaded hyalubilosomes embedded in dissolving PVA/PVP-chitosan microneedles as a minimally invasive topical acne treatment platform. The formulation was optimized using an I-optimal design and tested for physicochemical properties, morphology, stability, microneedle mechanical performance, in vitro release, ex vivo skin permeation, cytocompatibility, antioxidant activity, antimicrobial and antibiofilm effects, and in vivo acne efficacy. The study also examined the optimized system's potential to modulate inflammatory mediators and the Nrf2/HO-1/MYD88 signaling pathway in an acne-like inflammation model. Materials and methods Chemicals and reagents The following chemicals were used: Azelaic acid (Azelaic acid (≥98% pure, Sigma-Aldrich, USA), Hyaluronic acid (800-1000 kDa, Bloomage Biotech, China), Soybean Phosphatidylcholine (Lipoid S100, ≥94% pure, Lipoid GmbH, Germany), Tween 80 (Polysorbate 80, Sigma-Aldrich, USA), Bile salts which consists of Sodium Deoxycholate (NDC, ≥98% pure, Sigma-Aldrich, USA), Sodium Taurocholate (NTC, ≥98% pure, Sigma-Aldrich, USA), Chloroform (HPLC Grade, Sigma-Aldrich, USA), Methanol (HPLC Grade, Sigma-Aldrich, USA), Phosphate tungstic acid (2% w/v, Sigma-Aldrich, USA), Potassium Bromide (KBr; for IR pellets, Sigma-Aldrich, USA), Dimethyl sulfoxide (DMSO, ≥99.9% pure, Sigma-Aldrich, USA), and 2 N H2SO4 (Analytical Grade, Sigma-Aldrich, USA). Animals Thirty male Wistar albino rats, each weighing 150-200 g and aged 8 weeks, were allocated to five groups. The animals were housed in specifically designed, pathogen-free settings with a 12-h light/dark cycle, controlled humidity, and temperatures between 20 and 24 °C. They were afforded unrestricted access to partake in food and beverages. The experiment was conducted in accordance with the ARRIVE principles, as outlined in the “Guide for the Care and Use of Laboratory Animals.” The Research Ethics Committee (REC) of the Faculty of Pharmacy, Cairo University, approved the research. Approval Number: PI 3998. The research complied with the directives of the US National Institute of Health (NIH Publication No. 85–23, amended 2011) and the Guide for the Care and Use of Laboratory Animals. Methods Azelaic acid high-performance liquid chromatography analysis Azelaic acid can be analyzed and quantified utilizing a C₁₈ reversed-phase column (e.g., 250 × 4.6 mm, 5 μm, ODS-Hypersil) with an isocratic mobile phase comprising methanol and ammonium acetate buffer (20:80, v/v, pH 4.5) at a flow rate of 1.0 mL/min and UV detection at 230 nm, where azelaic acid exhibits significant absorbance (Han et al., 2013; Yang et al., 2022). A 20 μL sample volume was injected, and chromatography was performed at 25 °C. The amounts AZA were ascertained using a standard calibration curve. The calibration curve ranged from 20 to 100 μg/mL, with recovery rates of 97.13% to 102.04%. The linearity spanned from 20 to 100 μg/mL (R2 = 0.999; n = 3). Experimental design azelaic acid -loaded hyalubilosomes (AZA-HBs) The primary objective of the current design was to optimize an AZA-HBs formula to achieve enhanced EE% and ZP while minimizing PS and PDI. In preliminary screening, literature review, and our existing understanding of HBs formulation and development, independent variables potentially influencing these criteria were identified. An I-optimal design was employed using Design-Expert® version 13 (Stat-Ease, Inc., Minneapolis, MN, USA) to examine these variables and their interactions. The I-optimal design generated 22 experimental trials, as illustrated in Table 2. The independent variables chosen were: Hyaluronic acid concentration (A), amount of bile salts (B), and kinds of bile acid salts (C). The dependent variables selected were EE% (Y1), PS (Y2), PDI (Y3), and ZP (Y4), as illustrated in Table 1. Furthermore, we have established constraints on the target variables to facilitate the program in achieving the ideal formula by greatest numerical desirability. Table 2Fabrication of PVA/PVP-chitosan dissolving microneedles loaded with freeze-dried azelaic acid-loaded hyalubilosomes (AZA-HBs).FormulationsPVA (% w/w of total solids)PVP (% w/w of total solids)PVA/PVP-Cs-MNs16030PVA/PVP-Cs-MNs25040PVA/PVP-Cs-MNs34050Abbreviation: PVA, polyvinyl alcohol; PVP, polyvinyl pyrrolidone; Cs, chitosan; MNs, microneedles; AZA, azelaic acid; HBs, hyalubilosomes; AZA-HBs, azelaic acid-loaded hyalubilosomes; all formulations contain 10% w/w chitosan. Fabrication of PVA/PVP-chitosan dissolving microneedles loaded with freeze-dried azelaic acid-loaded hyalubilosomes (AZA-HBs). Abbreviation: PVA, polyvinyl alcohol; PVP, polyvinyl pyrrolidone; Cs, chitosan; MNs, microneedles; AZA, azelaic acid; HBs, hyalubilosomes; AZA-HBs, azelaic acid-loaded hyalubilosomes; all formulations contain 10% w/w chitosan. Table 1I-optimal design utilized for optimizing azelaic acid-loaded hyalubilosomes formulations.Factors (Independent variables)Design LevelsLow (-1)Medium (0)High (+1)A: Hyaluronic acid concentration2510B: Bile salts amount102030C: Bile acid salt typesNDCNTCSTGCResponses (Dependent variables)GoalY1: EE (%)MaximizeY2: PS (nm)MinimizeY3: PDI (nm)MinimizeY4: ZP (mV)MaximizeAbbreviations: NDC, sodium deoxycholate; NTC, sodium taurocholate; and STGC, sodium tauroglycocholate; EE, entrapment efficiency; PS, Particle size; PDI, polydispersity index; ZP, and zeta potential. I-optimal design utilized for optimizing azelaic acid-loaded hyalubilosomes formulations. Abbreviations: NDC, sodium deoxycholate; NTC, sodium taurocholate; and STGC, sodium tauroglycocholate; EE, entrapment efficiency; PS, Particle size; PDI, polydispersity index; ZP, and zeta potential. Preparation of azelaic acid-loaded hyalubilosomes (AZA-HBs) Hyalubilosomes were synthesized according to the methodology without the utilization of organic solvents (Othman et al., 2025)varying amounts of hyaluronic acid (HA) were combined with soybean phosphatidylcholine (SPC) and the necessary dose of azelaic acid (AZA) in distilled water. The dispersions were hydrated using continuous sonication for 8 h using a bath sonicator (32 °C, 30 kHz) until full hydration of HA with the phospholipid was attained. Subsequently, bile salt (STGC, NTC, NDC) and Tween 80 were incorporated into the hydrated dispersion as shown in Table 1, and the amalgamation was subjected to sonication for 16 h under identical conditions (bath sonicator, 32 °C, 30 kHz) until the formation of HA-coated hyaluronic acid (hyalubilosomes) was achieved, as shown in Fig. 1a. (See Fig. 2.) (a) Schematic diagram illustrates the methodology for preparing azelaic acid-loaded hyalubilosomes (AZA-HBs), and (b) Schematic diagram illustrates the methodology for fabrication of Optimized AZA-HBs-loaded PVA/PVP-Cs microneedle patches (AZA-HBs/PVA/PVP-Cs MNs). Experimental design of acne-like inflammation model and evaluation of azelaic acid formulations therapy in rats. In-vitro characterization of azelaic acid-loaded hyalubilosomes (AZA-HBs) Determination of particle size (PS), polydispersity index (PDI), and zeta potential (ZP) The physicochemical properties of azelaic acid-loaded hyalubilosomes were evaluated regarding particle size (PS), polydispersity index (PDI), and zeta potential (ZP). The HBs dispersion of AZA was analyzed at 25 ± 2 °C, using an aliquot of 0.1 mL, which was subsequently diluted 100-fold with double-distilled water to attain a concentration suitable for measurement of scattering intensity with the Zetasizer Nano ZS (Malvern Instruments; Worcestershire, UK) (Elhabal et al., 2026c; Hendawy et al., 2025). This methodology is based on the principles of dynamic light scattering, which arises from the stochastic motion of the scattered vesicles. PS, PDI, and ZP findings were documented in triplicate. Determination of AZA entrapment efficiency (EE%) The indirect method was employed to ascertain the entrapment efficiency of AZA-HBs. An aliquot (1 mL) of hyalubilosomal dispersion underwent ultracentrifugation (Sigma 3-30 KS cooling ultracentrifuge, Sigma Laborzentrifugen GmbH, Osterode am Harz, Germany) for 1 h at 22,000 rpm and a temperature of 4 °C (Elhabal et al., 2025f; Youssif et al., 2025). Untrapped AZA was measured in the supernatant by HPLC, as previously described, with UV detection at about 230 nm after a 1:10 dilution with methanol. The %EE data are displayed as (mean ± SD) from three distinct experiments. The following equation (Eq. (1)): Statistical optimization of AZA-HBs Using Design Expert® software, optimization was conducted to determine the parameter levels that achieve the minimum particle size (PS) and polydispersity index (PDI), as well as the maximum encapsulation efficiency (EE%) and the absolute value of zeta potential (ZP). Physicochemical characterization of the optimum formula Transmission electron microscopy (TEM) The morphology of the AZA-HBs was analyzed using TEM at 100 kV (JEM-2100; JEOL, Tokyo, Japan) to assess the influence of hyaluronic acid and bile salts on the properties of the AZA-HBs formulation. The collected samples were diluted with double-distilled water, and a single drop of the diluted sample was placed on a copper grid pre-coated with carbon and stained with phosphotungstic acid (2% w/v) (Elhabal et al., 2026b; M.H.H. Mohammed et al., 2023a). Thereafter, any surplus liquid was eliminated before analysis. Fourier transform infrared spectroscopy (FTIR) studies The optimized AZA-loaded HBs were lyophilized with 5% mannitol and frozen at −18 °C for 24 h. The frozen solution was further lyophilized in a freeze dryer (Labconco Corp., Kansas City, MO, USA) at −45 °C and a vacuum of 0.07 mbar for 48 h to get the lyophilized formula. FTIR analysis was performed to examine the functional groups of the pure drug and the drug-loaded HBs formulation. Spectra were independently obtained for azelaic acid, phospholipids, bile salts, and the formulation using an FTIR-8400 (Shimadzu, Kyoto, Japan). The sample-to-KBr ratio was preserved at 1:100, and the spectra were acquired within the range of 4000–400 cm−1 (Al-Zuhairy et al., 2025; Elhabal et al., 2025d). The drug-to-excipient ratio in the formulation was 1:4 (azelaic acid: soybean phosphatidylcholine, hyaluronic acid, and bile salts). Crystallinity examination via differential scanning calorimetry (DSC) studies A DSC study was conducted to evaluate the thermal characteristics and potential interactions of azelaic acid with excipients. A Shimadzu DSC-60 (Kyoto, Japan) was employed, and samples were heated at 10 °C/min from 0 to 170 °C under a nitrogen atmosphere (Elhabal et al., 2025b; Fouad et al., 2024). The drug-to-excipient ratio in the formulation was 1:4 azelaic acid: soybean phosphatidylcholine, hyaluronic acid, and bile salts. Thermograms were obtained for the pure drug, Blank HBs, and optimized AZA-HBs formulation to analyze thermal transitions. Effect of storage on the optimized AZA-HBs formula The optimized AZA-HBs formula was maintained at refrigerated (4 ± 1 °C) and ambient temperatures for 0, 3, and 6 months to assess its physical stability by comparing its EE%, PS, and PDI, and ZP before and after storage. Statistical significance was assessed using a Student's t-test in SPSS version 22.0. Differences at P ≤ 0.05 were deemed significant. The investigation was conducted three times to determine the mean ± SD (Mahdy et al., 2025; Mohamed et al., 2025). A dual-casting method was utilized to produce AZA-HBs-loaded PVA/PVP-chitosan microneedles (AZA-HBs/PVA/PVP-Cs-MNs) The needle tips were formulated using varying ratios of polyvinyl alcohol (PVA), polyvinylpyrrolidone (PVP), chitosan (2% w/v), and 5 mg of lyophilized azelaic acid-loaded hyalubilosomes (AZA-HBs), as specified in Table 2. The tip solution was formulated by dissolving PVA and PVP at 100 mg/mL each in distilled water; thereafter, lyophilized AZA-HBs and Chitosan (2% w/v) were added under gentle agitation until a homogeneous mixture was achieved. A volume of 60 μL of this tip solution was introduced into a 1 cm × 1 cm PDMS microneedle mold (Silicone Template ST-01; Micropoint Technologies Pte Ltd., Singapore) comprising 100 conical needles (300 μm height, 100 μm base diameter, 5 μm tip diameter, arranged in a 10 × 10 array) (Elhabal et al., 2026e; Sartawi et al., 2022). The vacuum application (20 min) guaranteed the complete filling of needle cavities without air entrapment. A drug-free backing solution (0.12 mg/mL PVA + 0.01 mg/mL Chitosan) was utilized as the second casting layer to improve adhesion and mechanical support. The filled molds were dried overnight at room temperature (25 °C) under light protection (Wang et al., 2025). The crosslinked hydrogel-forming microneedle patches were meticulously demolded and preserved in desiccators until characterization (Fig. 1b). Characterization of AZA-HBs-loaded PVA/PVP-chitosan microneedles (AZA-HBs/PVA/PVP-Cs-MNs) Drug content Individual microneedle arrays (n = 3) were dissolved in 10 mL of methanol: phosphate buffer (50:50 v/v, pH 5.5) and stirred (500 rpm, 24 h, 25 °C) to fully extract azelaic acid (AZA). The solution was filtered (0.45 μm PVDF) and analyzed using HPLC (C18 column, 250 × 4.6 mm, 5 μm; mobile phase: acetonitrile:0.1% phosphoric acid 40:60 v/v; flow rate 1.0 mL/min; detection 230 nm; injection 20 μL). AZA content was measured against a calibration curve (1-100 μg/mL, R2 > 0.999) and expressed as a percentage recovery compared to theoretical loading (Elhabal et al., 2025c; Ramadon et al., 2023). The following equation (Eq. (2)): Mechanical strength and penetration capability test The mechanical strength and skin penetration ability of AZA-HBs/PVA/PVP-chitosan microneedles (AZA-HBs/PVA/PVP-Cs-MNs) were determined using the Parafilm®M® penetration model. Eight layers of Parafilm® M® (0.13 mm/layer, total ∼ 1 mm thickness), a flexible olefin-based thermoplastic imitating the mechanical properties of human skin, were stacked and fastened at 25 °C. MN arrays (n = 3) were applied with standardized thumb pressure (32 N, corresponding to 3.2 kgf) for 30 s using a bespoke compression (Faizi et al., 2024; Fathy Elhabal et al., 2025; Prausnitz, 2004). After penetration, the Parafilm® layers were carefully removed, and holes were counted using an optical microscope (10× magnification). Individual needle height reductions and penetration depths were evaluated with digital calipers (0.01 mm precision). The mechanical strength and penetrating capacity were computed using the following Eqs. (3), (4) (Elhabal et al., 2026a). Acceptance criteria: <20% height loss and > 80% penetration through 4-6 Parafilm® layers, indicating adequate mechanical integrity for skin insertion. Water loss on drying (LOD) The LOD was calculated gravimetrically using the USP method. MN arrays (n = 3, initial weight ∼ 20 mg) were carefully weighed (W1), dried in a vacuum oven at 105 °C for 3 h or until constant weight, and reweighed (W2). The data from these measurements were analyzed using the following Eqs. (5) (Chanabodeechalermrung et al., 2024; Stoeva et al., 2025): Characterization of optimized microneedle Scanning electron microscopy (SEM) The morphology of the AZA-HBs/PVA/PVP-Cs-MNs patch was examined using a light microscope (Olympus Corporation, Tokyo, Japan) and a scanning electron microscope (SU8010, HITACHI, Tokyo, Japan). The AZA-HBs/PVA/PVP-Cs-MNs patch was attached to a microscope carrier and visualized at 6 kV with magnifications of 50×, 100×, 200×, and 600 × (Abu Ershaid et al., 2024; Hamed and Alhadidi, 2024). Fourier transform infrared (FTIR) analysis An FTIR spectrometer was used to record the room-temperature spectra of an AZA-HBs/PVA/PVP-Cs-MNs patch and its constituent parts between 4000 and 500 cm−1 (model 22, Bruker, Coventry, UK), as described previously (Rad et al., 2017; Sabbagh and Kim, 2023). Differential scanning calorimetry (DSC) The thermal properties, crystallinity, and interactions of the AZA-HBs/PVA/PVP-Cs-MNs patch were examined using differential scanning calorimetry (DSC-60; Shimadzu, Kyoto, Japan) at temperatures from 25 to 350 °C under nitrogen purge at 100 ml/min, as described previously (Elhabal et al., 2025a). Drug release studies Comparative in-vitro release study The in vitro release profiles of AZA-HBs, AZA-HBs/PVA/PVP-Cs-MNs, and an AZA suspension (5 mg/mL) were compared using the dialysis bag technique. The in vitro release of AZA from different formulations was performed using a USP dissolution testing apparatus type II (Hanson Research Corp, CA, USA) (Elhabal et al., 2025f; Venkatasubramanian et al., 2025). The dissolution media was 100 mL of phosphate buffer, pH 7.4, incorporating 25% methanol to ensure the sink conditions. (20%AZA) was placed in two open-ended tubes, with one end sealed with a dialysis membrane (12–14 kDa molecular mass cutoff). One tube was fixed to one side of the plastic cylinder, which was 7.5 cm long and 3 cm in internal diameter, and the other tube was attached to the dissolution apparatus shafts (Pal et al., 2021; Qu et al., 2016). The dissolution media temperature was maintained at 37 ± 1 °C, and the shaft was rotated at 50 rpm. At definite time intervals (1, 2, 4, 6, 8, 10, 12, and 24 h), 1 mL samples were taken from the dissolution media and replaced with an equal volume of fresh medium. The concentration of AZA was determined spectrophotometrically at λmax 230 nm. The in vitro release data were kinetically evaluated using various release models (Higuchi, first-order, Peppas, and zero-order) (Elhabal et al., 2025d). Ex vivo skin permeation study The ex vivo permeation of AZA from AZA suspension, AZA-HBs, and AZA-HBs/PVA/PVP-Cs-MNs was studied using vertical Franz diffusion cells. Excised rat skin was positioned between the donor and receptor compartments, with the stratum corneum facing the donor side. The receptor compartment was filled with phosphate buffer pH 7.4 containing 25% methanol and kept at 32 ± 0.5 °C with continuous stirring. Each formulation, equivalent to the same AZA dose, was administered to the donor compartment. Samples were taken from the receptor compartment at predefined intervals and promptly replaced with fresh receptor medium (Mahdy et al., 2025; Qaiser et al., 2024). AZA was measured using HPLC. The total amount penetrated per unit area, steady-state flow, permeability coefficient, and enhancement ratio were determined (Kadian et al., 2025; Zhang et al., 2024). The UV detector was adjusted to 230 nm, and the flow rate was 1 mL/min. All experimental techniques in the investigation were carried out in triplicate. In vitro cell toxicity assessment These formulations were tested on human skin with HaCaT keratinocytes from the American Type Culture Collection (ATCC Manassas, VA, USA) (PCS-201-012). The HaCaT cells were cultured in EMEM (Lonza, Walkersville, MD, USA) at a low Ca2+ concentration (0.03 mM), supplemented with 10% FBS and 1% penicillin/streptomycin (Invitrogen Inc., Carlsbad, CA, USA), at 37 °C in a humidified incubator, to perform a cell viability assay of the obtained AZA suspension and AZA-HBs MTT tests were used to determine the effects of AZA suspension and AZA-HBs on the viability of HaCaT cells (Quintero-Rincón et al., 2025; Wang et al., 2021). HaCaT cells were planted in 96-well plates at a density of 5 × 104 cells per well. Cells were exposed to AZA solution, AZA suspension, and AZA-HBs (10, 20, 30, 40, 80, and 160 μg/mL) for a full day. After the treatment, each well received 100 μL of fresh medium and 10 μL of MTT reagent (5 mg/mL; Sigma-Aldrich, St. Louis, MO, USA). The culture medium was then withdrawn (Fathy Elhabal et al., 2026b; Hartnett et al., 2015). The plate was incubated for 4 h at 37 degrees Celsius. After removing the medium, each well received 50 μL of DMSO and were incubated for 30 min. Using a microplate reader (Tecan, Mannedorf, Switzerland), absorbance was measured at 570 nm. The MTT experiment data were represented as the percentage of cells that were less viable than untreated (control) cells using the Turner BioSystems Modulus ™ microplate reader, made in California, and the average of three tests was calculated. Cell viability was determined using Eq. (6) (Al-Shabanah et al., 1994; Elhabal et al., 2025d). Antioxidant activity (DPPH radical scavenging assay) Two millilitres of AZA, AZA-HBs, and 0.1 mM DPPH solution were mixed in methanol for 40 min. Ascorbic acid (50 mg/20 mL MeOH, 0.008 mol) served as a positive control for antioxidant activity. Spectrophotometry measured absorbance between 200 and 800 nm with methanol as a blank. The liquid was swirled in an amber glass bottle for 45 min at 25 degrees Celsius. Spectrophotometry measured violet colour absorbance between 200 and 800 nm, and the antioxidant activity percentage was calculated using the following Eq. (7) (Fathy Elhabal et al., 2025; Yazici et al., 2025): Where A₀ = absorbance of DPPH control, A₁ = absorbance of sample/DPPH mixture. Assessment of antimicrobial activity Diffusion agar method The antibacterial activity of AZA, AZA-HBs, and AZA-HBs/PVA/PVP-Cs-MNs were investigated against selected pathogenic bacteria using the agar well diffusion technique. Gram-positive bacteria, such as Staphylococcus aureus ATCC 25923, Staphylococcus epidermidis ATCC 12228, and Streptococcus mutans ATCC 25175, were studied, as were Gram-negative bacteria, including Escherichia coli ATCC 25922. The standard microbial strains were obtained from the Regional Center for Mycology and Biotechnology (RCMB), Egypt. Bacterial suspensions were produced and added to Mueller-Hinton agar plates. Agar was divided into 6.0 mm diameter wells, with 100 μL of each tested sample added. The plates were incubated at 37 °C for 24 h. Gentamycin (4 mg/mL) was utilized as a positive control. Antimicrobial activity was determined by measuring the diameter of the inhibitory zones in millimeters (Alfaro-Viquez et al., 2020; Elhabal et al., 2025c). Assessment of the minimum inhibitory concentration (MIC) A two-fold broth dilution method was used to determine the minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) of AZA, AZA-HBs, and AZA-HBs/PVA-PVP/Cs MNs against the tested bacterial strains. A 96-well microplate filled with Muller-Hinton broth was filled with dilutions of AZA, AZA-HBs, and AZA-HBs/PVA/PVP-Cs-MNs at final concentrations of 2.5, 5, 10, 12.5, 25, 50, and 100 μM. Each bacterial strain under investigation was injected in equal quantities (106 CFU/ml). A microplate reader (Infinite M1000 Pro, Tecan, Switzerland) was used to measure absorbance at 600 nm after a 24-h incubation at 37 °C. The minimum concentration that prevented discernible growth was indicated by the MIC values (Borehalli Mayegowda et al., 2023; Chelminiak-Dudkiewicz et al., 2024). Antibiofilm assay and crystal violet staining (CVS) assay This study used 96-well microtiter plates with a 100 mL capacity to test concentrations ranging from 0.02 mg/mL to 25 mg/mL. Each extract's 10% stock solution was diluted twice in brain-heart infusion broth (BHI). The wells were incubated with 100 mL of each tested strain at 37 °C until the final concentration reached 1 × 106 CFU/mL. The medium served as the untreated control, 0.1% (w/v) CHX as the positive control, and 10% DMSO as the negative control. A 96-well microtiter plate was given to Staphylococcus epidermidis strains. The plates included an AZA, AZA-HBs, and AZA-HBs/PVA/PVP-Cs-MNs, and negative control (Abbasi et al., 2024; Won et al., 2023). To remove any stuck or moving cells, the wells were carefully emptied after 24 h, and the plates were cleaned with pH 7.4 phosphate buffer. The plates were baked for 45 min at 60 °C and then left to air dry. Applying 150 μL of 96% methanol to each well for 15–20 min fixed the adhering cells. Following plate removal, adherent cells were stained for 20 min at room temperature using 100 μL of a 0.1% crystal violet solution. To remove any remaining discoloration, the plates were washed with water at least 5 times. Biofilm biomass was quantified semi-quantitatively after 150 μL of 100% ethanol was used to resolubilize the crystal violet dye. After carefully and gently shaking the plates, the absorbance was measured at 620 nm using a microplate reader (Stat Fax 2100 microplate reader Spectrophotometer is made by Agilent Technologies, Inc., situated in Santa Clara, CA, USA). The mean absorbance (OD = 620 nm) of 252 samples was determined using the following Eq. (8), and the results were shown as % inhibition (Li et al., 2021; Shokri et al., 2018). In vivo study of anti-acne efficacy study using a rat ear acne-like inflammatory model An in vivo rat ear acne model was utilized to assess the anti-acne efficacy of AZA suspension, AZA-HBs, and AZA-HBs/PVA/PVP-Cs/MNs formulations. Rats exhibit skin and sebaceous gland physiology that closely mirror the pathophysiological mechanisms of human acne, making this model appropriate for evaluating the efficacy of innovative biotherapeutic polymer scaffolds on inflamed skin. Male Wistar albino rats weighing 150-200 g were used in the study (Elhabal et al., 2024; Sangnim et al., 2025). The auricles of the right and left ears were shaved and prepped by gently removing hair and surface debris using double-sided adhesive tape, followed by the application of a 2% coal tar solution to the inner surface of the right ear of rats once daily. The following day, a solution of Staphylococcus epidermidis (ATCC 12228) (1 × 106 CFU/mL) was injected subcutaneously into the right earlobe, approximately 100 μL per injection, every other day for a total of 14 days to establish a specific acne-like inflammatory reaction model. The left ear remained untreated and functioned as an internal control for each animal. After disease induction (modeling), the rats were randomly divided into five groups (n = 6 per group): Group I (Normal control): Healthy rats receiving no treatment. Group II (Diseased control): Disease-induced rats (positive control) receiving no treatment. Group III: Disease-induced rats treated with topical AZA suspension. Group IV: Disease-induced rats treated with AZA-HBs. Group V: Disease-induced rats treated with AZA-HBs/PVA/PVP-Cs-MN formulation. Each group was treated for a total of 9 days. On days 0, 3, 6, and 9 of treatment, the ear thickness of the experimental rats was measured with a vernier caliper and recorded. Photographs were taken on the 0 and 9 days of treatment. Similar. Prior to sacrifice, all animals were sedated intraperitoneally with a 10% ketamine and 2% xylazine (1:1) solution at a dosage of 0.1 mL per 100 g of body weight. Enzyme-linked immunosorbent assay (ELISA) for inflammatory markers The levels of tumor necrosis factor-alpha (TNF-α), interleukin-1 beta (IL-1β), interleukin-6 (IL-6), and Toll-Like Receptor 4 (TLR4) were measured in ear tissue homogenates utilizing commercially available sandwich ELISA kits (LifeSpan Biosciences, Inc., USA), in accordance with the manufacturers' guidelines (Cai et al., 2025; Saleem et al., 2020). Ear tissue samples from all experimental groups were homogenised in ice-cold buffer with protease inhibitors, then centrifuged at 4 °C; the cleared supernatants were collected for analysis. Standards and samples were introduced into the pre-coated microplate wells, followed by incubation with biotinylated detection antibodies and streptavidin–HRP conjugate. Colour development was achieved using the TMB substrate, and the reaction was terminated with 2 N H₂SO₄. Absorbance was measured at 450 nm using a microplate reader, and cytokine or protein concentrations were determined from the relevant standard curves and normalized to tissue weight (pg/g tissue). Quantitative real-time polymerase chain reaction (qRT-PCR) Total RNA was extracted from ocular tissues of all groups using QIAzol reagent (Qiagen, Germany), and RNA purity and concentration were measured spectrophotometrically (NanoDrop, Thermo Fisher Scientific, USA). A microgram of RNA was reverse transcribed into cDNA using the SensiFAST™ cDNA Synthesis Kit (Bioline, UK). The cDNA was then amplified on an Applied Biosystems 7500 real-time PCR system (USA) using HERA SYBR Green Master Mix (Willowfort, UK) under the following cycling conditions: 95 °C for 2 min, then 40 cycles of 95 °C for 10 s and 60 °C for 30 s. Each 20 μL reaction included 10 μL SYBR Green mix, 2 μL cDNA, 1 μL of each primer, and 6 μL of nuclease-free water. The 2-ΔΔCt method was used to calculate relative mRNA expression of (Nrf2) Nuclear factor erythroid 2–related factor 2 (Zhong et al., 2013), (HO-1) Heme oxygenase-1 (Weis et al., 2012), (MYD88) Myeloid differentiation primary response 88 (Wan et al., 2018), with GAPDH as the internal reference. Table 3 lists the primer sequences. Table 3The primer sequences used for amplification of the rat Nuclear factor erythroid 2–related factor 2, Heme oxygenase-1 M, and Myeloid differentiation primary response 88 genes.PrimerSequenceNCBI Reference SequenceAmplification SizeAnnealing TemperatureNrf2F: 5′-CTCTCTGGAGACGGCCATGACT-3′R: 5′-CTGGGCTGGGGACAGTGGTAGT-3′NM_031789.2146 bp60 °CHO-1F: 5′-GGAACTTTCAGAAGGGTCAGGTGTC-3′R: 5′-GCTGTGTGGCTGGTGTGTAAGG-3′NM_012232.2120 bp60 °CMYD88F: 5′-GATGGTAGCGGTTGTCTCTGAT-3′R: 5′-GATGCTGGGGAACTCTTTCTTC-3′NM_021964.3148 bp60 °CNote: Nrf2: Nuclear factor erythroid 2–related factor 2, HO-1: Heme oxygenase-1, MYD88: Myeloid differentiation primary response 88. F, forward primer; R, reverse primer. The primer sequences used for amplification of the rat Nuclear factor erythroid 2–related factor 2, Heme oxygenase-1 M, and Myeloid differentiation primary response 88 genes. Note: Nrf2: Nuclear factor erythroid 2–related factor 2, HO-1: Heme oxygenase-1, MYD88: Myeloid differentiation primary response 88. F, forward primer; R, reverse primer. Histopathological study Skin specimens were obtained from the dorsal region of the rat, which functioned as a standardized site for all subjects. After a 24-h immersion in a 10% buffered formalin solution, the specimens were excised, rinsed in xylene, and dehydrated with ascending ethanol concentrations prior to paraffin embedding. Serial skin segments were excised and positioned on glass slides to attain a thickness of five to seven micrometres. Tissue slices were generated, deparaffinized with xylene, and stained with hematoxylin and eosin (H&E) prior to histological examination using an electric light microscope (Mohanty et al., 2025; Wang et al., 2024). Immunohistochemical examination of epidermal growth factor (IHC-Peroxidase-DAB) Immunohistochemistry (IHC-Peroxidase-DAB) will be conducted to evaluate ear-surface inflammation in the acne model by analyzing the expression of epidermal growth factor (EGF) in the inflamed skin tissue. EGF is a crucial growth factor that plays a significant role in keratinocyte proliferation, wound healing, and inflammatory skin disorders, with its altered expression being linked to disrupted epidermal homeostasis in acneiform lesions. This investigation involves sectioning paraffin-embedded ear samples from various experimental groups at 4–5 μm and affixing them to adhesive glass slides. The slides will undergo deparaffinization in xylene and rehydration through a graded sequence of alcohol (100%, 95%, 70%) to distilled water. Endogenous peroxidase activity will be inhibited using 3% hydrogen peroxide for 10–15 min, followed by heat-induced epitope retrieval utilizing a citrate-based buffer (pH 6.0) in a pressure cooker or water bath to restore antigenicity. Following cooling and rinsing with phosphate-buffered saline (PBS), the sections will be incubated with the primary anti-EGF (IHC-Peroxidase-DAB) antibody for one hour at 25 °C in a humidified environment. After a comprehensive wash in PBS, the HRP-labeled detection system will be utilized according to the manufacturer's instructions: incubation with a secondary HRP-conjugated antibody, followed by development with 3,3′-diaminobenzidine (DAB) and counterstaining with hematoxylin. Negative control slides will be created by excluding the primary antibody while maintaining the identical secondary detection procedures to verify the specificity of the immunostaining (Henley et al., 2002; Larkina et al., 2025). EGF immunopositivity will be evaluated by calculating the mean percentage of stained area in five randomly selected high-power fields (400× magnification) for each group, utilizing image analysis software. The results will yield a semi-quantitative evaluation of EGF-mediated inflammatory activation and epidermal remodelling in the rat ear acne model. Statistical analysis Data analysis was done using GraphPad Prism 10 (GraphPad, USA), and the mean ± SD was calculated. One-way analysis of variance (ANOVA) with Tukey's test was used for multiple groups, whereas the t-test was used for two groups. p < 0.05 was considered statistically significant. Results In-vitro characterization of azelaic acid-loaded hyalubilosomes (AZA-HBs) Azelaic acid-loaded hyalubilosomes were optimized using an I-optimal design to achieve a nanocarrier with high entrapment efficiency (EE%), small particle size (PS), low polydispersity index (PDI), and high absolute zeta potential (ZP). The selected design levels and response targets (Table 1) enabled systematic screening of the factor space while maintaining a reasonable balance between model precision and experimental burden. The impact of formulation factors on entrapment efficiency (Y₁: EE%) The EE% of azelaic acid-loaded hyalubilosomes ranged from 55 ± 0.43% (run 21) to 90 ± 0.23% (run 2), with the optimized formula (OF) achieving 87 ± 0.55% (Table 4). The design was intended to maximize EE (Table 1), and the empirical evidence supports this across several formulations, especially at a mid-range of 5 mg hyaluronic acid, variable bile salt concentrations, and an appropriate bile salt type. Increasing bile salt concentration, while keeping hyaluronic acid constant, did not always result in an increase in EE. Some formulations containing 30 mg bile salts (runs 1, 13, 16) demonstrated moderate or low EE%, which could be attributed to an excessive amount of bile salts, leading to bilayer disruption and accelerated drug leaching (Kumar et al., 2023; Mondal et al., 2022).This reinforces the approach of adjusting bile salt concentration to enhance deformability while maintaining retention. The type of bile salt (C): STGC (sodium tauroglycocholate) runs (3, 4, 11, 15, 18, 19, 21, 22, OF) showed higher EE% and optimal PS, suggesting that this conjugation can provide a more stable and flexible bilayer than NDC or NTC. NTC (sodium taurocholate) and NDC (sodium deoxycholate) formulations (e.g. runs 6, 8, 10, 13, 14, 17) demonstrated a greater disruptive effect on vesicle structure with higher PS and variable EE (Choi et al., 2024; Torrisi et al., 2025). Hyaluronic Acid (A): At the low level (2 mg), formulations often had lower EE% (e.g., runs 12, 16, 21, 22), likely due to insufficient electrostatic shielding and lower bilayer stability (Aziz et al., 2019; Mosallam et al., 2021). Table 4Composition of azelaic acid-loaded hyalubilosomes with their measured responses (n = 3 ± SD).RunFactorsResponsesA:Hyaluronic acid amount (mg)B:Bile salts amount (mg)C:bile acid salts typesEE (%)PS (nm)PDI (nm)ZP (mV)11030NDC71 ± 0.43410 ± 0.540.54 ± 0.04-39 ± 0.452510NDC90 ± 0.23320 ± 0.660.51 ± 0.02-26 ± 0.693520STGC87 ± 0.65389 ± 0.430.49 ± 0.04-35 ± 0.874520STGC79 ± 0.76210 ± 0.380.36 ± 0.06-34 ± 0.675530NDC85 ± 0.66430 ± 0.870.48 ± 0.09-28 ± 0.936220NDC65 ± 0.23425 ± 0.580.45 ± 0.02-25 ± 0.377510NDC76 ± 0.65410 ± 0.770.43 ± 0.01-26 ± 0.488220NTC69 ± 0.34530 ± 0.560.49 ± 0.04-30 ± 0.569530NDC73 ± 0.54405 ± 0.410.43 ± 0.03-28 ± 0.73101020NDC62 ± 0.32430 ± 0.320.38 ± 0.04-37 ± 0.4711520STGC80 ± 0.54240 ± 0.430.29 ± 0.02-23 ± 0.5712210NTC61 ± 0.12620 ± 0.540.54 ± 0.01-30 ± 0.77131030NTC74 ± 0.58555 ± 0.670.51 ± 0.05-35 ± 0.45141020NTC77 ± 0.62520 ± 0.940.54 ± 0.03-32 ± 0.62151030STGC72 ± 0.35230 ± 0.590.31 ± 0.04-24 ± 0.5416230NTC59 ± 0.54509 ± 0.670.49 ± 0.03-27 ± 0.94171010NTC69 ± 0.45490 ± 0.980.42 ± 0.05-32 ± 0.45181010STGC70 ± 0.87210 ± 0.460.53 ± 0.01-34 ± 0.55191020STGC89 ± 0.46169 ± 0.430.21 ± 0.02-40 ± 0.3420520STGC84 ± 0.81234 ± 0.450.29 ± 0.01-27 ± 0.6521230STGC55 ± 0.43105 ± 0.650.36 ± 0.03-22 ± 0.6822210STGC56 ± 0.25196 ± 0.780.32 ± 0.02-24 ± 0.82OF619STGC87 ± 0.55170 ± 0.720.33 ± 0.01-29 ± 0.28Abbreviations: NDC, sodium deoxycholate; NTC, sodium taurocholate; and STGC, sodium tauroglycocholate; EE, entrapment efficiency; PS, Particle size; PDI, polydispersity index; ZP, zeta potential; and OF, optimized formula. Composition of azelaic acid-loaded hyalubilosomes with their measured responses (n = 3 ± SD). Abbreviations: NDC, sodium deoxycholate; NTC, sodium taurocholate; and STGC, sodium tauroglycocholate; EE, entrapment efficiency; PS, Particle size; PDI, polydispersity index; ZP, zeta potential; and OF, optimized formula. The intermediate (5 mg) and high (10 mg) levels of hyaluronic acid showed higher EE% in most cases (e.g., runs 2, 3, 4, 11, and 19), meaning that higher hyaluronic acid concentration leads to better partitioning of lipophilic azelaic acid into the bilayer or to the formation of a more compact and hydrated shell that minimizes drug loss. It is suggested that a combination of moderate hyaluronic acid (about 5-6 mg), with STGC as the bile salt type and an intermediate limit of about 20 mg of bile salt, gives the best possible EE without compromising the integrity of the vesicles (Miyake et al., 2025; Shalaby et al., 2026), as illustrated in Fig. 3a. 3D Response surface plot showing effect of A: Hyaluronic acid amount, B: Bile salts amount, C: bile acid salts types on (Y1) Entrapment efficiency percentage (E.E%) (a), (Y2) Particle size (P.S) (b), (Y3) polydispersity index (PDI) (c), and (Y4) zeta potential (Z.P) (d). Particle size (Y₂: PS) and effect of bile salt type and amount The PS of azelaic acid-loaded hyalubilosomes ranged from 105 ± 0.65 nm (run 21) to 620 ± 0.54 nm (run 12), with the optimized formula (6 mg HA, 19 mg bile salts, STGC) measuring 170 ± 0.72 nm (Table 4). The goal was to minimize PS (Table 1), and the optimized system falls within the recommended nanoscale range for topical and trans-follicular delivery (typically 100-300 nm). Low-size trends in STGC: STGC-containing formulations, particularly runs 19 (169 ± 0.43 nm) and OF (170 ± 0.72 nm), resulted in the smallest bilosome sizes, demonstrating that STGC promotes the production of compact, highly deformable structures (Dai et al., 2013a, Dai et al., 2013b). This is consistent with prior findings that specific bile salt conjugates can stabilize bent bilayers while decreasing vesicle size. Large PS with low HA and NTC/NDC: Formulations with 2 mg HA and NTC (runs 8, 12, 16, 17) resulted in significantly larger PS (509-620 nm), indicating insufficient surface coating by HA and substantial bilayer-disrupting effects of NTC, leading to aggregation or vesicle fusion. This supports hyaluronic acid's role as a stabilizing shell surrounding particle (HA-coated liposomes) (Aralelimath et al., 2024; Nayak et al., 2023a). Bile salt amount: Increasing bile salts from 10 to 30 mg at a constant HA generally increased PS (e.g., runs 10, 14, 13 with NTC; 1, 15 with STGC), showing that high bile salt content increases vesicle swelling and structural instability. The optimized formula (A = 6 mg, B ≈ 19 mg, C = STGC) produces a small PS (170 nm) by achieving a balance between enough bile salt to ensure deformability and sufficient hyaluronic acid to maintain small, stable vesicles, which is suitable for targeting the skin/hyaline layer as shown in Fig. 3b. Polydispersity index (Y₃: PDI) and homogeneity The PDI of the hyalubilosomes ranged from 0.21 ± 0.02 (run 19) to 0.54 ± 0.04 (runs 1, 6, 12), with the optimized formula showing 0.33 ± 0.01, indicating a reasonably narrow size distribution around the mean (Table 4). For monomodal, reproducible systems, a PDI of less than 0.3 is typically desirable. Low PDI with STGC and moderate HA: Formulations including STGC and 5-10 mg HA (e.g., runs 19, 11, 4, 20, OF) had the lowest PDI values (0.21-0.29), indicating a uniform, unimodal population. This indicates that STGC, when combined with sufficient HA, promotes homogeneous vesicle production during hydration. High PDI with NTC/NDC and low HA: Runs with NTC or NDC and 2 mg HA (e.g., 8, 12, 16) showed PDI > 0.4, indicating a larger, heterogeneous size distribution, most likely caused by spontaneous aggregation or uneven bilayer curvature (Mitrović et al., 2025). STGC-based, hyaluronic acid-stabilized hyalubilosomes are the most reproducible and well-suited for scale-up, as evidenced by the optimized formula (C = STGC, A ≈ 6 mg, B ≈ 19 mg) shown in Fig. 3c. Zeta potential (Y₄: ZP) and colloidal stability The ZP of azelaic acid-loaded hyalubilosomes varied between -22 ± 0.68 mV (run 21) and -40 ± 0.34 mV (run 19), with the optimized formula attaining -29 ± 0.28 mV (Table 4). The goal was to maximize ZP (Table 1), and most formulations fell within or near the typically accepted stability range (ZP ≥ 25-30 mV).STGC with 10 mg HA resulted in the greatest negative ZP (−39 to −40 mV) in runs 1, 15, and 19, suggesting substantial electrostatic repulsion between particles. Hyaluronic acid acts as a polyanionic coating, increasing negative surface charge and resistance to aggregation (HA-coated liposomes). Formulations with NTC or NDC and 2 mg HA (e.g., 8, 12, 16, 17) had lower negative ZP (≈ − 25 to −30 mV), indicating reduced colloidal stability. Compared to the optimized formula, run 19 (10 mg HA, 20 mg STGC) produced EE ≈ 89%, PS ≈ 169 nm, PDI ≈ 0.21, and ZP ≈ −40 mV, outperforming the recommended OF on all parameters (Harini et al., 2025; Sideek et al., 2024). The I-optimal algorithm selected the OF (A = 6 mg, B ≈ 19 mg, C = STGC) based on constraints such as cost, HA loading, and ease of scale-up. This shows that model-based optimization is effective but may sacrifice extreme performance for practicality, as shown in Fig. 3d. The performance of the optimized AZA-HBs presents positive comparisons to the previously reported AZA nanocarrier systems. The optimized AZA-HBs showed an entrapment efficiency of 87.0 ± 0.55%, a particle size of 170 ± 0.72 nm, PDI of 0.33 ± 0.01, and zeta potential of -29 ± 0.28 mV. These values are demonstrative of excellent AZA encapsulation and formation, nanosized vesicular, and colloidal stability. For comparisons, Mistry and Ravikumar developed AZA-loaded ethosomes that were used for the treatment of acne and reported an optimized vesicular size of 4.25 ± 1.35 μm with an entrapment efficiency of 91.86 ± 2.25% (Mistry et al., 2016). Even though the ethosome system had a slightly higher percentage of entrapment efficiency, the vesicular size was in the micrometer range, whereas the current AZA-HBs system achieved a much smaller size in the nanoscale range, which could be beneficial for dermal penetration and local retention. Malik and Kaur also developed AZA-loaded nanostructured lipid carriers and reported an optimized entrapment efficiency of 83.4 ± 2.14% with a particle size of 49.6 ± 1.24 nm that further demonstrated the enhancement of topical performance of AZA nanocarriers (Malik and Kaur, 2018). Statistical optimization and model validation The I-optimal design produced a statistically supported model for each response (Y₁: EE%, Y₂: PS, Y₃: PDI, and Y₄: ZP), allowing for reasonable selection of an optimized azelaic acid-loaded hyalubilosome formula (Table 5). The observed responses encompassed EE% from 55% to 90%, PS from 105 to 620 nm, PDI from 0.21 to 0.54, and ZP from −22 to −40 mV, suggesting a broad yet relevant experimental area. The EE% response (Y₁) was best matched by a quadratic model (R2 = 0.807, adjusted R2 = 0.594, predicted R2 = 0.821). The model had a significant F-value of 3.79 (P = 0.022) and an adequate accuracy of 6.292, showing reasonable predictive potential. Factor A (hyaluronic acid quantity) was revealed as the most significant influencing factor on EE%, consistent with previous findings that intermediate to high HA levels improve entrapment by stabilizing the bilayer and enhancing drug partitioning (Shen et al., 2024). The PS (Y₂) response followed a linear model with high statistical significance (F-value = 42.74, P < 0.0001; R2 = 0.909, adjusted R2 = 0.888, projected R2 = 0.841; acceptable precision = 14.175). Significant differences in PS between STGC-based systems (smaller vesicles, e.g., runs 19 and OF) and NTC/NDC-based systems (larger vesicles) can be attributed to the bile salt type (C). PS's excellent R2 and appropriate precision values demonstrate its good predictability within the design area. The PDI (Y₃) response was fitted with a linear model (F-value = 8.68, P = 0.0005; R2 = 0.671, adjusted R2 = 0.594, predicted R2 = 0.500; sufficient precision = 8.045). Only C (bile salt type) was found to be a significant influence, with STGC-containing formulations producing the lowest PDI values (0.21-0.29), indicating a homogeneous, monomodal size distribution. The linear model was appropriate for ZP (Y₄) (F-value = 3.06, P = 0.0033; R2 = 0.419, adjusted R2 = 0.282, predicted R2 = 0.072; adequate precision = 4.815). The major determinants were A (the amount of hyaluronic acid) and B (the amount of bile salt), indicating that the polyanionic HA shell and bile salt concentration regulate surface charge. Despite lower R2 and expected R2 for ZP compared to PS or EE%, the model nevertheless demonstrated appropriate predictive power (precision >4.0) for the optimization process. Using established models, the I-optimal design algorithm identified an optimized formula (A = 6 mg hyaluronic acid, B = 19 mg bile salts, C = STGC) with anticipated responses that closely match experimentally observed values (Table 2): EE% ≈ 87%, PS ≈ 170 nm, PDI ≈ 0.33, ZP ≈ -29 mV. The I-optimal design successfully balanced high EE%, small PS, low PDI, and sufficiently negative ZP, resulting in a stable, nano-sized hyalubilosome system suitable for azelaic acid delivery. This is supported by significant model F-values, acceptable R2, and adequate precision metrics. Table 5Output data of I-optimal design utilized for optimizing azelaic acid-loaded hyalubilosomes formulations.ResponsesY1: EE%Y2: PSY3: PDIY4: ZPMinimum551050.21-22Maximum906200.54-40ModelQuadraticLinearLinearLinearF- value3.7942.748.683.06P-value0.022< 0.00010.00050.0033R20.8070.9090.6710.419Adjusted R20.5940.8880.5940.282Predicted R20.8210.8410.5000.072Adequate Precision6.29214.1758.0454.815Significant factorsACCA, B Output data of I-optimal design utilized for optimizing azelaic acid-loaded hyalubilosomes formulations. Stability study The stability investigation of the optimized azelaic acid-loaded hyalubilosomes (AZA-HBs) formulations, as shown in Table 6, shows that the systems retained acceptable physicochemical properties throughout a 6-month storage period under both refrigerated (4 ± 1 °C) and ambient conditions. After 6 months of storage, the encapsulation efficiency (EE%) decreased marginally from 87 ± 0.55% to 82 ± 0.23% at 4 ± 1 °C and from 85 ± 0.11% to 83 ± 0.38% at ambient temperature, indicating minimal azelaic acid leakage from the vesicles. The particle size (PS) increased from 170 ± 0.72 nm to 183 ± 0.93 nm under refrigeration and from 173 ± 0.94 nm to 182 ± 0.74 nm at ambient temperature. This suggests a small degree of vesicle aggregation or mild fusion over time, but the values remained within the nanoscale range suitable for dermal delivery. The polydispersity index (PDI) increased from 0.33 ± 0.01 to 0.38 ± 0.09 at 4 ± 1 °C and from 0.37 ± 0.01 to 0.41 ± 0.02 at room temperature, indicating a gradual increase in size heterogeneity. However, the PDI did not exceed the generally acceptable threshold (PDI < 0.5), indicating that the dispersion remained relatively monodisperse. The zeta potential (ZP) values were consistently negative (approximately -28 to -29 mV) throughout all time points and storage settings, indicating robust electrostatic stabilisation of the colloidal system and negligible aggregation. Overall, these results demonstrate that the optimized AZA-HBs exhibit adequate short- and medium-term stability, with refrigeration providing only a marginal improvement compared to ambient storage, indicating the potential of these nanovesicles as a stable topical delivery system for azelaic acid. Table 6Stability study for optimized azelaic acid-loaded hyalubilosomes (AZA-HBs) formulations.Storage timeRefrigerated Temperature (4 ± 1 °C)Ambient temperatureEE (%)PS (nm)PDIZP (mV)EE (%)PS (nm)PDIZP (mV)After 24 h87 ± 0.55170 ± 0.720.33 ± 0.01-29 ± 0.1885 ± 0.11173 ± 0.940.37 ± 0.01-29 ± 0.433 months85 ± 0.15175 ± 0.760.34 ± 0.06-28 ± 0.3883 ± 0.34178 ± 0.340.38 ± 0.07-29 ± 0.356 months82 ± 0.23183 ± 0.930.38 ± 0.09-28 ± 0.8383 ± 0.38182 ± 0.740.41 ± 0.02-29 ± 0.18Data are displayed as mean ± SD from three independent tests (n = 3). Stability study for optimized azelaic acid-loaded hyalubilosomes (AZA-HBs) formulations. Data are displayed as mean ± SD from three independent tests (n = 3). Characterization of the optimum AZA-HBs Transmission electron microscopy (TEM) The TEM investigation (Fig. 4a) revealed that the vesicles were distinct, nearly spherical nanostructures with smooth outlines, indicating the successful creation of a well-organized vesicular system. The detected particle diameters were in the nanometric range, between 129.62 nm to 166.23 nm, which agrees well with the vesicle size previously determined by dynamic light scattering. The somewhat reduced diameter observed by TEM could be attributed to imaging of dry particles, whereas the hydrodynamic diameter measured by the zetasizer reflects the hydrated state of the vesicles (Dai et al., 2013a; Zarif Attalla et al., 2025). The generated nanovesicles' spherical and non-aggregated form indicates good homogeneity and structural stability. (a)TEM micrograph of optimized azelaic acid-loaded hyalubilosomes (AZA-HBs), (b) Fourier Transform Infrared Spectroscopy, and (c) Differential Scanning Calorimetry for pure azelaic acid (AZA), Blank hyalubilosomes (Blank-HBs), and azelaic acid-loaded hyalubilosomes (AZA-HBs). Fourier-transform infra-red spectroscopy (FTIR) Fig. 4b shows the FTIR spectra of AZA, Blank-HBs, and AZA-HBs, which were utilized to study AZA's compatibility with the excipients and demonstrate its successful incorporation into the bilosomal and microneedle matrices. Pure AZA's spectra shows characteristic absorption bands at 3300-3400 cm-1, attributed to the stretching vibration of the carboxylic acid's O-H group. The sharp band at 1695-1705 cm-1 represents the C Created by potrace 1.16, written by Peter Selinger 2001-2019 O stretching vibration of the carboxylic acid moiety and is the main distinctive peak of AZA. Additional bands were found at about 2920 cm-1 and 2850 cm-1, representing the asymmetric and symmetric stretching of aliphatic -CH₂ groups, respectively. Peaks at 1460-1470 cm-1 and 1410-1430 cm-1 correspond to bending vibrations of CH₂/OH groups, while bands at 1280 cm-1, 1240 cm-1, and 1110-1120 cm-1 are due to C-O stretching vibrations (Elhabal et al., 2026d). These findings are consistent with the distinctive fingerprint of AZA. Blank-HBs' spectrum showed the primary bands of the vesicular components. A broad band appears about 3400-3435 cm-1, which is assignable to O-H stretching, primarily resulting from cholesterol and other hydroxyl-containing substances. Furthermore, discrete aliphatic stretching bands were found at about 2935 cm-1, 2900 cm-1, 2865 cm-1, and 2850 cm-1, corresponding to the asymmetric and symmetric stretching vibrations of CH₂ and CH₃ groups in the lipid bilayer (Arshad et al., 2024; Ricci et al., 2024). The presence of these peaks confirms the successful creation of the blank vesicular system. AZA-HBs weaken, broaden, or partially cover the characteristic AZA bands, particularly the prominent C Created by potrace 1.16, written by Peter Selinger 2001-2019 O peak at ∼1700 cm-1, compared to pure AZA. Similarly, the broad O-H stretching region was less defined and overlapped with the hydroxyl band of the vesicular components (Elhabal et al., 2026e; Nayak et al., 2023b). The reduced intensity and/or partial removal of AZA-specific peaks in loaded bilosomes indicated that the drug was no longer present as a free crystalline substance but had been successfully entrapped within the vesicular structure. This behavior could be ascribed to hydrogen bonding and hydrophobic interactions between AZA and the bilosomal components, resulting in the dispersion of the medication within the vesicle matrix. Differential scanning calorimetry (DSC) Fig. 4c depicts the DSC thermograms of AZA, Blank-HBs, and AZA-HBs, which were used to evaluate the drug's physical state and interaction with formulation components. The thermogram of pure AZA revealed a distinct acute endothermic peak at around 267-270 °C, corresponding to its melting point and confirming its crystalline composition. The sharpness of this peak shows that the medication exists in a highly organized crystalline state prior to formulation. AZA-HBs lost their acute melting endotherm at around 267-270 °C. Instead, the thermogram revealed only a faint or widened thermal event at 180-190 °C, which corresponded primarily to the vesicular matrix. The total absence of the AZA melting peak indicates that the medication lost its crystalline structure and got absorbed in an amorphous, solubilized, or molecularly dispersed state inside the bilosomal system (Kawar and Abdelkader, 2019; Teixeira et al., 2017). This finding provides compelling evidence for effective drug trapping within nanovesicles. Physicochemical characterization of AZA-HBs/PVA/PVP-Chitosan microneedles Drug content The synthesized microneedles exhibited azelaic acid (AZA) contents of 93.7 ± 1.2% for PVA/PVP-Cs-MNs1, 95.3 ± 1.2% for PVA/PVP-Cs-MNs2, and 88.3 ± 0.6% for PVA/PVP-Cs-MNs3, in relation to theoretical loading as shown in Fig. 5a. The results indicate that lyophilized AZA-HBs were effectively incorporated into the microneedle matrix, demonstrating superior recovery during mold casting and drying processes. The highest drug content observed in MNs2 demonstrates that the 50:40:10 ratio of PVA:PVP:chitosan achieved optimal formulation uniformity and vesicle retention. The reduced recovery in MNs3 can be attributed to its high PVP content, which increases hydrophilicity and promotes partial drug redistribution during drying, whereas MNs1 efficiently kept the drug but did not outperform MNs2. The studies demonstrate that MNs2's balanced polymer composition reduced formulation loss and more efficiently maintained AZA-HB integrity relative to the other formulations (Asaf et al., 2025; Elhabal et al., 2026e). This aligns with research demonstrating that combining Chitosan with water-soluble polymers such as PVP and PVA improves release control and structural effectiveness in dissolving microneedles. (a-d) Physicochemical Characterization of AZA-HBs/PVA/PVP-Chitosan Microneedles (a) drug content, (b)Mechanical Integrity assessment, (c)Skin Penetration Capability, (d)Water Loss on Drying (LOD); (e-g) characterization of optimized microneedles, (e) digital image captured by using a light microscope, (f) Scanning electron microscopy, (g)in vitro drug release, and (h)Skin ex vivo permeation study. Data are presented as mean ± SD (n = 3). Statistical significance was analyzed using one-way ANOVA followed by post hoc comparisons; * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001. Mechanical integrity assessment The data showed that the reduction in microneedle height under 32 N of thumb pressure applied for 30 s was 12.7 ± 0.6% for MNs1, 11.0 ± 1.0% for MNs2, and 15.3 ± 0.6% for MNs3. All formulations showed sufficient mechanical strength under mechanical stress for dermal insertion, as shown in Fig. 5b. MNs2 showed the greatest mechanical properties, indicating that the 50:40:10 ratio provided the best balance of stiffness and flexibility. This is likely due to the combination of PVA and PVP, where PVA enhances the polymers' ability to form a film and provides structural cohesion, while PVP increases tensile strength and the rate of hydration. Chitosan enhances the polymer matrix and increases the toughness of the needle tip (Elhabal et al., 2025c; Lee et al., 2008). MNs3 had the highest PVP content and showed the greatest deformation, likely due to excessive hydrophilicity, which increased water absorption and softened the system's matrix during compression. These mechanical properties of the formulations are in line with studies showing that polymers enhance microneedle strength and ease of insertion. The Parafilm® model's skin penetration capability The 8-layer Parafilm® M penetration test MNs2 showed the most positive penetration profile, achieving 97.8% hole formation in Layer 3, 92% penetration in Layer 4, and 28% residual penetration in Layer 8 as depicted in Fig. 5c. These results indicate that MNs2 can penetrate the skin barrier quickly and form uniform microchannels across multiple skin layers. The enhanced penetration of MNs2 is due to its mechanical properties: a formulation that resists compression without becoming overly brittle is more likely to retain sharper needle tips during insertion. MNs1 demonstrated sufficient penetration but lower efficacy than MNs2. In contrast, MNs3 appeared to exhibit lower efficacy due to greater deformability resulting from the higher PVP content. This relationship between mechanical strength and penetration efficacy underscores the importance of achieving the right balance of polymers in the formulation for transdermal delivery (Elhabal et al., 2025a; Matadh et al., 2023). Chitosan-blended microneedles have been shown to achieve fairly high penetration through Parafilm when the polymer ratios are optimized, and the matrix maintains sharpened tips to avoid breakage upon insertion. Water loss on drying (LOD) assessment As shown in Fig. 5d, the LOD values were determined as 3.7 ± 0.6% for MNs1, 3.2 ± 0.2% for MNs2, and 4.3 ± 0.6% for MNs3. All formulations met the 5% moisture threshold, indicating adequate drying, and demonstrated good storage stability. MNs2 had the least residual moisture, suggesting that the optimal PVA/PVP ratio, together with Chitosan, provided the best control of drying and moisture retention. The increased LOD for MNs3 may be related to the higher PVP, since PVP is highly hygroscopic and thus absorbs moisture more quickly than PVA. Although the differences may be small, they are significant in formulation, as residual moisture may negatively affect brittleness, storage stability, and long-term handling of MNs. The consistent low LOD results indicate that the microneedles were adequately dried, allowing them to remain stable during prolonged storage under normal conditions. This agrees with other studies suggesting that PVP-containing microneedles exhibit higher moisture absorption, whereas Chitosan can improve moisture absorption by increasing matrix density and moisture absorption capacity. MNs1 (60:30:10) shows adequate drug retention and good mechanical properties but does not achieve a satisfactory overall balance. MNs2 (50:40:10) is the best formulation, with the greatest sustained drug release, the least reduction in height, the best level of penetration, and the best level of pharmacopoeial testing, with the lowest detection limit (LOD). MNs3 (40:50:10) is adequate but considerably weaker than the other samples in mechanical strength and drug recovery, likely due to PVP-induced flip and saturation hydrophilicity. PVA/PVP-Cs-MNs2 is the best formulation, achieving greater encapsulation efficiency and mechanical strength, along with enhanced penetration ability and drying stability, confirming that a 50:40:10 ratio of polymers is optimal for AZA-HBs-loaded dissolving microneedles (Aroche et al., 2025; Elhabal et al., 2025e).The LOD test was used to determine the remaining moisture content in the dissolving microneedle matrix. Residual moisture is an important quality attribute for polymeric microneedles because excessive moisture can soften the needle tips, reduce mechanical strength, impair insertion efficiency, increase drug degradation, and compromise storage stability. As a result, LOD was used to assess appropriate drying and formulation stability, especially since PVP is hygroscopic and may increase moisture uptake within the polymeric matrix. The PVA/PVP/Chitosan matrix was chosen to balance mechanical strength and dissolving behavior (Fathy Elhabal et al., 2026). PVA was added to increase film formation and structural strength, PVP to improve hydration and dissolution after insertion, and Chitosan to strengthen the polymeric network and improve skin adherence. This polymeric mixture was designed to retain AZA-HBs in the microneedle tips during casting and drying, while enabling effective release after skin penetration. Characterization of optimized microneedles Scanning electron microscopy (SEM) Morphological analysis was performed using a light microscope (Fig. 5e), and SEM micrographs are known for powerfully illustrating the integrity and uniformity of the architecture of fabricated microneedles (Fig. 5f). At lower magnifications, vertical microneedles exhibit a distributed, uniform, parallel arrangement. Uniformity of construction and order demonstrates notable control over microneedle construction and guarantees a microneedle patch with a reproducible, consistent interaction with the skin. This is important for consistent drug delivery, reproducible insertion, and removal. In magnified images of individual microneedles, the conical and pyramidal shapes exhibit distinct, sharp, well-defined tip structures. Sharp tips significantly influence the microneedle's resistance. Generally, reductions in force and efficient delivery can be achieved with a well-formed, pointed tip (Elhabal et al., 2026a; Gupta and Yadav, 2019; Zhou et al., 2024). At the same time, the broad base of each needle supports the structure and helps maintain sufficient mechanical strength during application. The integrity of the structure is essential for maintaining the mechanical strength of microneedles. Microneedles, by design, rupture the desired membrane without collapsing during insertion. Structural integrity ultimately determined the mandrel structure of the microneedles. The design and microneedle construction provide a logical assurance for sustained function during application and microneedle insertion without failure of the needle to deliver and rupture the target membrane. Microneedles manufactured with extensive polymer solidification techniques and casting or molding techniques likely exhibit polymer surface roughness and small surface defects that are generally not pronounced and go unnoticed at standard inspection levels. These features are likely due to solvent evaporation or drying-induced solidification. These imperfections are unlikely to produce cracks or defects that would compromise the microneedle array's efficacy, but rather support the microneedles' uninterrupted, continuous surface presence. Importantly, the photographs reveal the microneedles are integrated with the baseplate. From a functional standpoint, microneedles manufactured with a continuous and compact backing layer are considered microneedle patches. The ability of the baseplate to support the microneedles and transmit the baseplate's force to them during skin penetration is the most important functional element of the baseplate. Well-integrated microneedle architectures and compact backing layers diminish the probability of individual microneedle dislodgment and enhance the mechanical integrity of the overall structure (Anjani et al., 2023; Duarah et al., 2023). The findings are definitive and illustrate the successful fabrication of a microneedle array with sharp tips, uniform geometries, and integrated microneedle configurations. These attributes enhance mechanical dependability, ensure uniform microneedle penetration, and optimize overall product performance, rendering the microneedles very appropriate for transdermal applications. Microneedle technology is expected to improve the transdermal distribution of the integrated formulation and boost overall therapeutic efficacy. The SEM results unequivocally demonstrate that the microneedles are designed to improve therapeutic administration by penetrating further into the stratum corneum during application. Comparative in-vitro release study Fig. 5g shows the in vitro release results that show significant differences between free AZA, AZA-HBs, and AZA-HBs/PVA/PVP-Cs-MNs after 48 h. Free AZA had the fastest release rate, contributing to 19% at 1 h, 25% at 4 h, 40% at 10 h, and 45% at 48 h. The rapid profile indicates that the non-encapsulated drug was readily available to the release media, suggesting an insignificant diffusion barrier. On the other hand, AZA-HBs showed a more gradual and controlled release: 15% at 1 h, 20% at 4 h, 39% at 10 h, and 43% at 48 h, suggesting that vesicular entrapment restricted the drug's diffusion and limited its rapid release. AZA-HBs/PVA/PVP-Cs-MNs had a release profile that was the most consistent, showing 17% at 1 h, 21% at 4 h, 36% at 10 h, 40% at 12 h, 43% at 16 h, 42% at 24 h, 44% at 48 h, and 95% at the optimum formulation. The gradual increase in release indicates that the microneedle matrix provided an additional diffusion barrier in addition to the hyalubilosome vesicle. The dual delivery system most likely provided more controlled, prolonged drug delivery, which is desirable for the treatment of acne, because AZA benefits from local, prolonged exposure rather than rapid release, which can trigger inflammation. The microneedle formulation significantly improved cumulative release compared with AZA-HB alone. Of the systems evaluated, AZA-HBs/PVA/PVP-Cs-MNs at 24 h achieved 90-92%, AZA-HBs sustained 68-70%, and free AZA accounted for only 43-44%. After 48 h, microneedle formulations achieved 94-95% results, compared with AZA-HBs (69-71%) and free AZA (43-45%). It is therefore proposed that the microneedle array improves both the efficiency and the duration of drug delivery. The polymeric microneedle matrix is crucial for elucidating this phenomenon. PVA and PVP are hydrophilic polymers that rapidly swell in water, maximizing water absorption while minimizing the rate of drug delivery. Chitosan increases mechanical stability, which can slow matrix degradation, improve skin adhesion, and prolong adhesion time. In addition, the inclusion of hyalubilosomes protected the encapsulated azelaic acid, not only limiting rapid degradation but also substantially reducing the initial burst release of unencapsulated formulations (X. Fan et al., 2025b; Stoeva et al., 2025). The incorporation of microneedles into the release medium enables the complex processes of hydration, expansion, and final disintegration or relaxation of the polymeric network, thereby allowing encapsulated AZA-HBs to diffuse freely. These criteria are crucial in the management of acne. AZA is utilized for its antibacterial, anti-inflammatory, and keratolytic attributes. A formulation that offers sustained exposure for 24-48 h will improve efficacy while reducing the frequency of administration. The release profile of AZA-HBs/PVA/PVP-Cs-MNs, compared to free AZA, is more appropriate for the topical treatment of acne because it offers improved release, skin retention, and overall drug availability. The results from this study confirm microneedle technology as a promising drug delivery system, with cumulative release ranging from 17% at 1 h to 95% at 48 h in the optimal formulation. This suggests that incorporating AZA-HBs into PVA/PVP-chitosan microneedles enables control over release profiles, potentially providing improved localized acne treatment. Kinetics study The release kinetics indicate that the Korsmeyer-Peppas model best describes all three formulations, suggesting that azelaic acid release is predominantly governed by diffusion, with additional influence from matrix relaxation contingent on the system, as shown in Table 7. Free AZA showed the lowest R2 values for the zero- and first-order models, yet the highest for the Korsmeyer-Peppas model (R2 = 0.948), suggesting a diffusion-controlled release mechanism rather than a constant rate. AZA-HBs exhibited superior alignment with the Korsmeyer-Peppas model (R2 = 0.987) compared to the Higuchi model (R2 = 0.965), indicating that vesicular entrapment enhanced release regulation, with both diffusion and structural relaxation contributing to drug transport. The AZA-HBs-MNs exhibited optimal fit to the Korsmeyer-Peppas model (R2 = 0.980), signifying that the microneedle matrix regulated AZA release while facilitating effective diffusion across the hydrated polymer matrix (Kral et al., 2024; Šedbarė et al., 2023). The n values offer a more accurate elucidation of the releasing mechanism. For free AZA, n = 0.323, which is below 0.45, signifying Fickian diffusion. This indicates that the medication was predominantly released by concentration-driven diffusion. The release of AZA-HBs was regulated by a combination of diffusion, relaxation, and enlargement of the hyalubilosomal matrix (n = 0.628, ranging from 0.45 to 0.89), signifying anomalous transport. For AZA-HBs-MNs, n = 0.393 signifies Fickian diffusion. This indicates that once the microneedles were hydrated, AZA diffused from the system via polymer channels instead of through erosion-dominated release. The statistics indicate a clear advancement in release control from a formulation perspective. Free AZA represents the least regulated system, while AZA-HBs enhance the release profile by vesicular encapsulation. AZA-HBs-MNs provide the most effective transdermal platform, as the microneedle matrix introduces an extra barrier that regulates drug escape while facilitating efficient delivery (Marwa Hassan Hussaen Mohammed et al., 2023a). This is crucial in acne treatment, as sustained local exposure is favored over a transient application that may induce irritation or reduce skin retention time. Korsmeyer-Peppas's comprehensive description of all three systems supports the assertion that diffusion is the principal mechanism governing AZA release in all examined formulations. The Korsmeyer-Peppas model most accurately characterizes the release kinetics of free AZA, AZA-HBs, and AZA-HBs-MNs, indicating diffusion-dominated release across all formulations. Free AZA and AZA-HBs-MNs exhibited Fickian diffusion (n < 0.45), while AZA-HBs revealed anomalous transport (n < 0.89), signifying a blend of diffusion and matrix relaxation inside the hyalubilosomal carrier. Table 7Kinetics analysis of the release behavior of azelaic acid from the optimum azelaic acid -loaded hylabilosomes (AZA-HBs), its corresponding PVA/PVP-chitosan microneedles loaded optimum azelaic acid -loaded hylabilosomes and azelaic acid suspension.FormulationZero Order (R2)First Order (R2)Higuchi (R2)Korsmeyer–Peppas (R2)n (Peppas)Best Fit ModelFree AZA0.6920.7460.9130.9480.323Korsmeyer–PeppasAZA-HBs0.8370.9100.9650.9870.628Korsmeyer–PeppasAZA-HBs-MNs0.7810.9560.9620.9800.393Korsmeyer–PeppasNote: AZA, azelaic acid; AZA-HBs, azelaic acid-loaded hyalubilosomes; AZA-HBs-MNs, optimized azelaic acid-loaded hyalubilosomes microneedles. Kinetics analysis of the release behavior of azelaic acid from the optimum azelaic acid -loaded hylabilosomes (AZA-HBs), its corresponding PVA/PVP-chitosan microneedles loaded optimum azelaic acid -loaded hylabilosomes and azelaic acid suspension. Note: AZA, azelaic acid; AZA-HBs, azelaic acid-loaded hyalubilosomes; AZA-HBs-MNs, optimized azelaic acid-loaded hyalubilosomes microneedles. Skin ex vivo permeation study The ex vivo permeation studies indicate that the AZA-HBs/PVA/PVP-Cs-MNs exhibit superior performance compared to free AZA or AZA-HBs alone (Fig. 5h). The total penetration after 48 h was around 545–540–538 for free AZA, 2600–2540–2500 for AZA-HBs, and 3400–3450–3400 for AZA-HBs-MNs. This indicates that the microneedle technique was most effective in facilitating transdermal medication delivery. The microneedle formulation enhanced absorption by approximately 6.3 times after 48 h compared to free AZA, whereas AZA-HBs alone raised it by roughly 4.8 times. This unequivocally endorses the advantages of integrating vesicular encapsulation with microneedle-assisted administration. An effective way to understand the profile is to examine the early, middle, and late temporal regions. After one hour, free AZA exhibited little permeation, whereas AZA-HBs attained approximately 100–120, and AZA-HBs-MNs achieved 400–432. After four hours, the differentiation became distinctly apparent: free AZA ranged from 60 to 66, AZA-HBs fluctuated between 230 and 239, whereas AZA-HBs-MNs spanned from 590 to 640. This signifies that the microneedles enabled the prompt transdermal delivery of the drug across the stratum corneum barrier. The hyalubilosomes enhanced drug penetration, although they did not achieve the efficacy of the active microchannel delivery offered by the microneedles (Wu et al., 2022; Zaid Alkilani et al., 2023). The primary mechanistic rationale is that the microneedles presumably generated temporary aqueous microchannels in the skin, thereby promoting the deeper infiltration of AZA-HBs into the tissue and augmenting their diffusion into the viable epidermal and dermal strata. PVA and PVP absorb moisture and expand upon touch, enabling release. Conversely, Chitosan helps preserve the needle's integrity and may improve skin adhesion. Microneedle technology improves permeability and modifies the distribution's trajectory and velocity by substantially diminishing the integrity of the epidermal barrier. The incremental rise from 435 to 540 at 1 h to 3400–3450 at 48 h signifies a steady permeation pattern rather than a sudden spike. This feature is advantageous for acne treatment, as AZA is more effective when retained on the skin for extended periods rather than quickly evaporating from the application site. In contrast, free AZA demonstrated slow and limited penetration, as expected, because it must penetrate the intact stratum corneum without the assistance of a carrier. AZA-HBs alone significantly enhanced penetration, reaching approximately 2600–2500 at 48 h. This demonstrates that the HBs carrier enhanced the solubility and transport of azelaic acid more efficiently than the unencapsulated formulation. At the last time point, the microneedle formulation exhibited an efficacy around 30–35% more than that of AZA-HBs (Mohammed et al., 2023b). This illustrates that the synergistic application of HBs and microneedles surpasses the efficacy of utilizing either method in isolation. This corroborates the principle of dual delivery: the carrier improves the organization and stability of the drugs, while the microneedles breach the primary barrier of the skin. The results may also be compared to systems that use nanostructured lipid carriers (NLCs) for AZA and are designed to enhance dermal retention. Kumari and colleagues synthesized AZA-loaded NLCs with a mean particle size of 81.57 ± 9.6 nm, with a PDI of 0.208 ± 0.021 and a zeta potential of −29.3 ± 1.21 mV. Their NLC gel exhibited an ex vivo permeation of 21.06 ± 0.99%, which is still lower than the permeation of AZA gel (38.71 ± 1.47%) and AZA solution (78.79 ± 2.52%), while the AZA-gel solution (63.96 ± 4.56%) and the AZA solution (4.78 ± 1.1%) and the AZA-gel solution (15.12 ± 3.2%) demonstrated significantly lower retention. This suggests that the primary function of nanocarriers is local dermal retention and not systemic retention. On the other hand, the AZA-HBs/PVA/PVP-Cs-MNs currently designed aim to enhance AZA delivery while maintaining a constant local therapeutic effect by providing sustained local release and dermal retention through microneedle technology. In vitro study Cellular viability study The findings from the cell viability study demonstrated a clear level of difference between AZA-HBs/PVA/PVP-Cs-MNs and free azelaic acid, as illustrated in Fig. 6a. The blank control showed near 100% cell viability, indicating that the test materials were responsible for the observed changes. At all concentrations tested, free AZA was cell-lethal to HaCaT cells, demonstrating that the unencapsulated free form of the acid was highly toxic to these cells. The microneedle-loaded hyalubilosomal formulation demonstrated a significant improvement in viability with increasing concentration, achieving approximately 54–60% at the highest concentration tested. This indicates a significant improvement in biocompatibility. The carrier system significantly contributes to this improvement. Unencapsulated azelaic acid is in form that is readily available for cellular interaction and could potentially lead to cell membrane disruption and impact the cell's mitochondria or other critical cell functions. The formulation design, in which the drug is incorporated into HBs and then integrated into the PVA/PVP-chitosan microneedle matrix, promotes delayed, controlled release. This also decreases the probability of cells being exposed to the drug at the same time; thus, the cells appear to be less negatively impacted by the drug. This is a very important property in a topical formulation because it indicates that the treatment can be provided with less pain and irritation and increased safety (Elhabal et al., 2024). The improvement of survivability at the high concentration of the microneedle formulation may be due to the carrier's ability to protect and slowly release the drug rather than a direct dose response relationship to the drug itself. The formulation appears to ensure the active ingredient remains effective while remaining cell-compatible. Compared to free azelaic acid, the formulation AZA-HBs/PVA/PVP-Cs-MNs shows improvement in skincare applications. In vitro biological evaluation of AZA suspension, Blank HBs, and optimized AZA-HBs /PVA-PVP-Cs MNs: (a) cell viability in HaCaT keratinocytes and (b) DPPH radical scavenging activity. Data are presented as mean ± SD (n = 3). Statistical significance was analyzed using one-way ANOVA followed by post hoc comparisons; ns = not significant, * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001. Antioxidant activity assay All the samples displayed some degree of antioxidant activity, even though the DPPH results were varied, as illustrated in Fig. 6b. Ascorbic acid was the most effective positive control. Unbound azelaic acid was also effective as an antioxidant. At the lowest concentration, the antioxidant scavenging activity was minimal, and was maximal at the highest concentration. Antioxidant activity for the AZA-HBs/PVA/PVP-Cs-MNs was significant, although it was slightly less than free azelaic acid at most concentrations. The slight decrease is due to some of the azelaic acid being sequestered in the hyalu-bilosomes and microneedle matrix during the assay, so it could not be readily available to the DPPH radicals. The formulation does not change the antioxidant activity; it only results in a delayed manifestation of the activity (Khan et al., 2025; Quintero-Rincón et al., 2025). Overall, for a delivery system of this nature, secluding the azelaic acid is an acceptable trade-off; the prolonged activity in the antioxidant assay supports the formulation's intended purpose. The increase in scavenging activity correlates to the concentration, which indicates that the antioxidant properties of the azelaic acid were retained. The microneedle formulation demonstrated a significant radical scavenging effect even at high levels, indicating that a certain amount of the medicine was sufficient to respond to DPPH. In situations such as this, this is of utmost importance, as oxidative stress increases inflammation and makes acne and other skin conditions worse. It is therefore extremely important to maintain antioxidant activity to improve overall health. The results of the two experiments combined show that AZA-HBs/PVA/PVP-Cs-MNs is the most secure and effective formulation. Among the tested actives, free AZA had the most pronounced direct impact on living cells but was also the most destructive to the cellular integrity. The HBs combined with the microneedles approach decreased cytotoxicity while retaining a considerable fraction of the antioxidant properties. This suggests that the formulation will be beneficial for topical acne treatment with localized action while sparing the integrity of surrounding skin cells. Cell viability tests showed that free azelaic acid completely destroyed HaCaT cells at all measured doses. In comparison, AZA-HBs/PVA/PVP-Cs-MNs showed a remarkable improvement in cell compatibility, with cell viability reaching approximately 54-60% at the highest concentration. In the DPPH test, unformulated azelaic acid had a slightly better free radical scavenging ability than the formulated system, but AZA-HBs/PVA/PVP-Cs-MNs still possessed considerable antioxidant activity. The results suggest that the combination of azelaic acid with HBs and microneedles decreased cytotoxicity while maintaining antioxidant activity, thereby confirming the formulation's suitability for topical use. Antimicrobial assay Antimicrobial activity Agar diffusion assay (Fig. 7a and b) unequivocally demonstrates that the antibacterial effect is contingent upon the concentration and formulation. AZA-HBs/PVA/PVP-Cs-MNs (3) exhibited the largest zones of inhibition against all examined pathogens, including Staphylococcus epidermidis, Escherichia coli, Staphylococcus aureus, and Streptococcus mutans. The heightened activity relative to both AZA suspension (1) and blank microneedles (2) indicates that including AZA into the HBs/PVA/PVP-Cs microneedle matrix significantly enhances its bactericidal efficacy. The blank formulation demonstrated moderate inhibition, likely attributable to the intrinsic antibacterial properties of chitosan (Cs) and possibly components derived from hesperidin. The AZA-loaded formulation demonstrated comparable or superior inhibitory zones relative to the standard antibiotic (gentamycin) in multiple cases, highlighting its strong, broad-spectrum antibacterial effectiveness. Statistical analysis further corroborates the importance of these changes (p < 0.05 to p < 0.001), indicating a reliable augmentative effect. Antibacterial activity of AZA-loaded HBs/PVA/PVP-Cs microneedles against selected pathogenic bacteria: representative (a) agar well diffusion plates assay, (b)comparative zones of inhibition, and (c) Minimum inhibitory concentration (MIC). Note: (1)azelaic acid (AZA) suspension, (2)blank hyalubilosomes-based polyvinyl alcohol/polyvinyl pyrrolidone/Chitosan microneedles (blank HBs-PVA/PVP-Cs-MNs), and (3) azelaic acid-loaded hyalubilosomes-based polyvinyl alcohol/polyvinyl pyrrolidone/Chitosan microneedles (AZA-HBs/PVA/PVP-Cs-MNs); (A)Staphylococcus epidermidis, (B) Escherichia coli, (C)Staphylococcus aureus, and (D)Streptococcus mutans, expressed as zone of inhibition (mm). Data are presented as mean ± SD (n = 3). Statistical significance was analyzed using one-way ANOVA followed by post hoc comparisons; ns = not significant, * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001. This is essential as S. aureus, S. epidermidis, and S. mutans are associated with microbial load on the skin and in the oral cavity, but E. coli serves as a Gram-negative counterpart. AZA is recognized for its ability to eradicate bacteria responsible for skin infections, and the microneedle method appears to facilitate its transport into the test medium, thereby enhancing the antibacterial response. The agar well diffusion assay revealed that AZA-HBs/PVA/PVP-Cs-MNs produced the largest zones of inhibition for all evaluated species. The enhanced microneedle formulation demonstrated zones of around 29–31 mm for S. epidermidis, while the blank microneedles exhibited zones of 20–22 mm, and the AZA solution showed zones of 24–26 mm (Nagaraja et al., 2025; Ong et al., 2022). The Gentamicin zones measured around 28 mm. The new approach demonstrated performance at least equivalent to, and in several cases superior than the reference medicine against this infection. The enhancement likely indicates enhanced dispersion of AZA from the hyalubilosome-microneedle matrix and superior contact with the agar medium. The AZA-HBs/PVA/PVP-Cs-MNs exhibited the largest inhibitory zones against E. coli, measuring approximately 45–48 mm. The uncoated microneedles measured 35–36 mm, the AZA suspension measured 40–41 mm, and gentamicin measured 30–31 mm. This illustrates strong antibacterial activity, especially against the Gram-negative strain, which can be more difficult to suppress due to its outer membrane. The expanded region indicates that the microneedle formulation enhanced the dispersion and accessibility of azelaic acid within the experimental framework. The improved formulation produced 46–49 mm against S. aureus, while the AZA suspension produced 42–25 mm, depending on the order of the duplicates. The unfilled formulation produced 33–36 mm. The microneedle technique was most effective in arresting the process. S. mutans demonstrated a comparable pattern. The AZA-HBs/PVA/PVP-Cs-MNs ranged from 46 to 50 mm, the AZA suspension ranged from 43 to 48 mm, and the blank microneedles ranged from 35 to 41 mm (Alfaro-Viquez et al., 2020; Huang et al., 2022). The diffusion experiment demonstrates that the ultimate microneedle formulation was the most efficacious antibacterial system. Minimum inhibitory concentration activity The MIC findings suggest that AZA-HBs/PVA/PVP-Cs-MNs were superior to other treatments, especially when attacking Gram-positive bacteria, as demonstrated in Fig. 7c. The microneedles exhibited a MIC against Staphylococcus aureus of 7-8 μg/mL. The AZA solution had a MIC of 16–19 μg/mL, while the blank microneedles had a MIC of 29–33 μg/mL. The smaller MIC was a result of the formulation needing a smaller amount of a drug to achieve a suppression of bacteria growth, irrefutably indicating superior activity against corresponding pathogens. In a like manner, the optimized microneedles against S. mutans exhibited a MIC of 7–8 μg/mL. The AZA suspension was 6–8 μg/mL, while the blank microneedles were 30–33 μg/mL. The low MIC demonstrated that the final microneedle formulation had superior efficacy at a lower concentration for inhibiting bacterial growth. This may be due to newly designed carrier systems that have improved the controlled release of azelaic acid, thereby helping maintain sustained contact with bacteria. The MIC of AZA-HBs/PVA/PVP-Cs-MNs against E. coli was 50–52 μg/mL, and blank microneedles and AZA suspension had a MIC of 30–32 μg/mL and 15–17 μg/mL, respectively. The formulation exhibited lower activity against E. coli in the MIC test compared with the zone-of-inhibition test. This is a normal occurrence, as the two test samples assess various aspects of antibacterial behavior. Diffusion, which sometimes benefits samples that spread readily across the agar, contrasts with MIC, which entails a more rigorous sampling of the liquid environments of the sample. The minimum inhibitory concentration (MIC) of the AZA-HBs/PVA/PVP-Cs-MNs against Staphylococcus epidermidis was 60-65 μg/mL. While this is worse than the blank formulation (125-128 μg/mL), it is better than the AZA suspension (62-64 μg/mL), signifying moderate antimicrobial activity. Compared to the blank carrier, the microneedle formulation had better diffusive and active carrier activity. The carrier showed higher active carrier activity in the solid diffusion experiment than in the MIC assay. The overall activity pattern shows that the microneedles enhanced the antibacterial activity of the AZA in the agar diffusion, and the microneedle formulation also exhibited better drug delivery and local bioavailability at the site of action. However, the blank HBs-PVA/PVP-Cs-MNs showed significant MIC diffusion, likely due to the properties of the polymer matrix and the partial diffusion of the microneedles and the agent. However, the diffusion of the azelaic acid showed to have the greatest antibacterial effect (Shalaby et al., 2026). The azelaic acid now shows better diffusion in the MIC activity, while the blank carrier shows better activity in the bioavailability. Antibiofilm activity Fig. 8 shows that (3: AZA-HBs/PVA/PVP-Cs-MNs) had the highest efficacy in anti-biofilm activity against S. epidermidis, followed by (1:AZA suspension). (2; blank HBs-PVA/PVP-Cs-MNs) exhibited the lowest anti-biofilm efficacy among all the formulations evaluated. AZA-HBs/PVA/PVP-Cs-MNs exhibited the highest inhibition in the 75% MIC condition, demonstrating 96.75% anti-biofilm activity. AZA suspension exhibited a percentage of 86.57%, whereas blank HBs-PVA/PVP-Cs-MNs demonstrated a percentage of 85.08%. The enhanced microneedle formulation was the most effective at inhibiting S. epidermidis from developing biofilm. Epidermidis is crucial for acne treatment since this bacterium contributes to skin infection, inflammation, and persistent infection. AZA-HBs/PVA/PVP-Cs-MNs exhibited a substantial anti-biofilm efficacy of 90.83% at 50% MIC. AZA suspension exhibited a percentage of 82.28%, while blank HBs-PVA/PVP-Cs-MNs demonstrated a percentage of 68.11%. This indicates that the AZA-HBs/PVA/PVP-Cs-MNs combination exhibited greater potency despite a reduced dosage (Koohestani et al., 2018; Wojnicz et al., 2016). This indicates a stronger interaction with the bacterial biofilm matrix, enhancing the availability of AZA in the vicinity. The diminished activity noted with blank HBs-PVA/PVP-Cs-MNs indicates that this formulation was less efficacious in disrupting or suppressing biofilm formation, possibly attributable to discrepancies in drug release, vesicle loading, or polymer equilibrium. The alterations were significantly more evident at 25% MIC. AZA-HBs/PVA/PVP-Cs-MNs had a notable anti-biofilm efficacy of 84.76%. The effect of AZA suspension diminished to 39.59%, whereas the effect of blank HBs-PVA/PVP-Cs-MNs decreased to merely 23.37%. AZA-HBs/PVA/PVP-Cs-MNs demonstrated efficacy at elevated doses while maintaining activity at reduced concentrations, which is a significant advantage for a topical acne treatment. A formulation that maintains biofilm inhibition at reduced concentrations could be more clinically beneficial, as it may alleviate discomfort and diminish the potential of inadvertent toxicity while effectively preventing bacterial adhesion and biofilm formation. The significant anti-biofilm effect of AZA-HBs/PVA/PVP-Cs-MNs can be attributed to the synergistic action of hyalubilosome encapsulation and microneedle administration. AZA have antibacterial and anti-inflammatory properties. When combined with a carrier system, the medication can more effectively reach the germs. Microneedles may facilitate penetration beyond the stratum corneum into deeper skin layers, where S, epidermidis biofilms may persist. The polymeric matrix may facilitate sustained local release, maintaining drug concentrations sufficient to inhibit biofilm formation and stability. In terms of functionality, inhibiting biofilms is typically more challenging than eradicating planktonic bacteria due to the protective extracellular polymeric matrix that impedes medication penetration. AZA-HBs/PVA/PVP-Cs-MNs robust efficacy indicates that the formulation may have inhibited early adhesion, impeded matrix formation, or facilitated the penetration of the medication into the biofilm. This is particularly beneficial for acne, where S. epidermidis. The formation of epidermidis biofilm can result in extended colonization and therapeutic resistance (Al-Shamiri et al., 2023; Santos Manzi et al., 2025). The evidence supports the notion that the optimized microneedle formulation is superior for acne treatment compared to the other formulation examined. The blank carrier system demonstrated some action, but significantly lower than that of the drug-loaded variant. The polymer matrix alone does not contribute to the efficacy of the anti-biofilm action. The action is mostly attributed to AZA. The microneedle-hyalubilosome system enhances distribution and efficacy. The synergy appears to function by integrating the physical penetration advantages of AZA with its inherent antibacterial properties, hence enhancing the overall anti-biofilm efficacy. (a). Crystals violet assay to assess antibiofilm activity on Staphylococcus epidermidis, and (b)Antibiofilm reduction effect of S. epidermidis; (1) azelaicd (AZA) suspension, (2)blank hyalubilosomes-based polyvinyl alcohol/polyvinyl pyrrolidone/chitosan microneedles (blank HBs-PVA/PVP-Cs-MNs), and (3) azelaic acid-loaded hyalubilosomes-based polyvinyl alcohol/polyvinyl pyrrolidone/chitosan microneedles (AZA-HBs/PVA/PVP-Cs-MNs). Data are presented as mean ± SD (n = 3). Statistical significance was analyzed using one-way ANOVA followed by post hoc comparisons; ns = not significant, * p < 0.05, and **** p < 0.0001. In vivo study Fig. 9. presents compelling in vivo evidence that various azelaic acid (AZA)-based formulations effectively cure acne in rat ears. The figure combines qualitative and quantitative evaluations by comparing photographic images and measuring ear thickness throughout the treatment period. These results provide a comprehensive overview of the efficacy of the evaluated systems in combating acne and inflammation. The control group showed no signs of swelling or redness, thus serving as a physiological standard for healthy ear anatomy. For the positive control group, which included the untreated diseased rats, the ear surfaces exhibited substantial evidence of irritative changes, such as swelling, redness, and deformation. These changes illustrate the successful implementation of the inflammatory model using the acne-like irritative ear model, and that due to the nature of the model, inflammatory edema and irritation of tissues will be present even in the absence of the therapeutic model. The group that applied the topical AZA suspension had a marked improvement in comparison to the positive control group. This was indicative of the presence of a therapeutic effect of AZA on the inflammatory condition. This was in line with what is known about the pharmacological attributes of AZA, which include its antibacterial properties, its ability to break down keratin, and its anti-inflammatory effect. AZA is known to reduce the inflammatory response and the formation of free radicals in skin tissues and to down-regulate the inflammation caused by acne. The suspension of AZA had a marginal improvement on the condition, indicating that the standard dosage form available of the therapeutic agent may be inadequate due to a lack of trans-epidermal and permeability adequate to reach and be retained in the deeper tissues (that are the site of the inflammatory process). Although the AZA suspension had a marginal effect, the advanced formulations with a higher concentration of AZA had a better effect in the same condition, indicating that the improvement in the dermal drug delivery system was warranted. In vivo evaluation of different formulation of azelaic acid treatment for rat ear acne. (a) Comparative image after acne treatment in rats. Group I: Normal Group; Group II: Positive; Control (Diseased Group);Group III administered a topical application of AZA suspension; Group IV was given AZA-HBs; and Group V received the AZA-HBs/PVA/PVP-Cs-MN formulation. (b) Changes in rat ear thickness with treatment duration. The carrier system has most likely improved the area's medication accessibility and the duration of contact with the inflammatory tissue. These improvements could be because of the medication's characteristics and increased interaction at the skin's surface. AZA-HBs perform better than the formulation AZA-HBs and its free AZA solution. This helped further develop the technique, as a formulation design will serve as a medication delivery system, free of restrictions, while still alleviating the issues of conventional topical treatments (Shankar et al., 2021; Varani et al., 2006). They exhibited the positive effects of the ear's original skin, along with decreased and improved inflammatory responses in the area. This was due to ear bumps caused by an increased cellular matrix and exudates that protected it from the effects of the stimuli. The continuous ear bumps seen in the positive control demonstrate the extent of the pathogenesis. However, the treated groups showed a decrease in ear bumps. They exhibited varied characteristics and rates of improvement. These groups displayed a continuous, positive treatment response, with the AZA suspension showing the least improvement, while the AZA head block gels showed the most improvement. Compared to the other tested formulations, the AZA-HBs/PVA/PVP-Cs-MN formulation caused the most painful ear bursts, coming closest to matching the peaked group. The microneedle-based product eliminated the changes associated with the development of acne in the mouse. The AZA-HBs/PVA/PVP-Cs-MN formulation outperformed the others for several reasons. First, microneedle technology likely increased the efficacy of drug transport beyond the stratum corneum, the most significant barrier to topical drug delivery. The microneedles would create microscopic channels in the skin, allowing AZA to reach deeper regions of the epidermis and dermis. This would improve the medicine's accessibility to deeper tissues of the body. Acedenia is especially important. It is extremely important for the tissues surrounding the affected areas and deeper tissues involved within and surrounding the follicle. The polymeric matrix containing PVA, PVP, and Cs likely assisted in microneedle formation, thereby improving drug loading and release efficiency. Third, Chitosan may offer additional therapeutic properties beyond its other benefits. The greater the therapeutic properties, the longer the formulation remains at the site of application. The improved results with the AZA-HBs/PVA/PVP-Cs-MN formulation may be due to the enhanced biological activity and physical drug distribution effects observed with the microneedles. Sustained drug-release systems can improve the efficacy of an acne treatment by maintaining a drug concentration that is effective for longer periods, reducing the previously observed discrepancies in exposure/blood levels, and reducing the frequency of dosing. The capacity for local, prolonged, and continuous release of the drug will ensure the drug's constant availability to subdue the activities of microorganisms, support the inflammatory process of the skin, and help repair skin loss. The continuous steady thickening of the ear tissue in this case supports the theory as well. Also, the photographic images and the tissue from the same groups in the normal control group show that inflammation can be reduced and tissue integrity restored. One important factor is that the tissue differences in the treated groups show that the treatment cannot be in any way attributed to the concentration of AZA alone. The identical active molecule produced markedly different outcomes in vivo, depending on its method of synthesis. This highlights the significance of advanced drug delivery systems in improving the therapeutic effectiveness of current anti-acne therapies. The results shown in Fig. 9 provide substantial evidence that the microneedle-based formulation significantly improves AZA efficacy, resulting in enhanced clinical outcomes compared to conventional topical administration. Inflammatory markers and quantitative real-time polymerase chain reaction (qRT-PCR) assay Fig. 10. illustrates the impact of several azelaic acid (AZA)-based formulations on key inflammatory and oxidative stress biomarkers in the rat ear acne model. This enhances our comprehension of their efficacy as treatments. The evaluated markers include pro-inflammatory cytokines (IL-1β, TNF-α, and IL-6), the innate immunological receptor TLR4, and oxidative stress-related genes (Nrf2, HO-1, and MyD88), collectively reflecting the extent of inflammation, immune activation, and redox imbalance associated with acne etiology. In Group II, the epicenter, the levels of the main inflammatory cytokines IL-1β, TNF-α, IL-6, TLR4, and MyD88 were markedly elevated when compared with the normal group I. This confirmed the activation of a pronounced inflammatory response (see Fig. 10a-d). Additionally, numerous abnormalities and rigidity of the defense system were discovered in the affected group. This was particularly evident in the pronounced downregulation of the genes Nrf2 and HO-1 (shown in Fig. 10e-g). The above results suggest the holistic importance of TLR4/MyD88 signaling and oxidative stress in the pathogenesis of acne inflammation. The AZA suspension (Group III) response was confirmed, as AZA markedly decreased the inflammatory response compared with the positive control group. This was confirmed through the significant reduction of IL-1β, TNF-α, and IL-6 levels. In addition, TLR4 and MyD88 expression levels were partially restored. The slight increase of Nrf2 and HO-1 levels confirmed the antioxidant effect of AZA. The response was also confirmed by reduced pro-inflammatory cytokines and by inhibition of the TLR4/MyD88 inflammatory cascade (Cai et al., 2025; Nieto et al., 2020). The antioxidant mechanism of the disorder was identified as being in the positive control AZA group. This restoration effect confirms the HBs system of AZA and the increased bioavailability of AZA. Enhanced control of inflammatory and oxidative processes in this group suggests that the carrier system significantly improves AZA's therapeutic performance. The AZA-HBs/PVA/PVP-Cs-MN group (Group V) showed the most significant results. It showed the lowest levels of IL-1β, IL-6, TNF-α, TLR4, and MyD88, even compared to the normal group, in all treatment groups. This formulation also caused the greatest increase in Nrf2 and HO-1 expression, demonstrating a significant effect on restoring the cell's defense systems. The results show that this microneedle-based device effectively reduces inflammation and enhances cellular defense systems against oxidative stress. Substantial downregulation of TLR4/MyD88 signaling indicates that this formulation targets key early signaling pathways that trigger and amplify inflammatory responses in acne. The AZA-HBs/PVA/PVP-Cs-MN formulation is the most effective among the formulations. It is likely that microneedle technology enhances the transdermal delivery of AZA to deeper layers of the skin. The use of a polymeric system comprising PVA, PVP, and Chitosan is likely to control drug release and the duration of drug retention at the application site, while Chitosan is likely to have a favorable tissue-healing effect due to its anti-inflammatory and antibacterial effects. The exceptional changes in inflammatory and oxidative markers in this group are likely due to improved drug penetration, sustained release, and the bioactivity of the carrier system. These biomarkers confirm that, within the model, acne progression is associated with unregulated pro-inflammatory cytokines and the TLR4/MyD88 signaling cascade, as well as compromised antioxidant defense mechanisms. AZA may only partially reverse these changes. However, because of new delivery technologies for improving AZA's treatment capacity, AZA-HBs/PVA/PVP-Cs-MNs displayed the greatest efficacy of all the examined formulations in managing the inflammatory and oxidative responses. Thus, AZA-HBs/PVA/PVP-Cs-MNs may have the dual capacity to manage acne and restore balance to the body's oxidative and reductive processes. Effects of different treatments on inflammatory biomarkers measured by ELISA: (a)IL-1β, (b)TNF-α, (c)IL-6, (d) TLR4, and qRT-PCR analysis demonstrating the relative transcription levels of Nrf2 (e), HO-1 (f), and MYD88 (g). Data are expressed as mean ± SD (n = 10). * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001, and ns (not significant) versus the control group. Abbreviations: Group I: Normal Group; Group II: Positive; Control (Diseased Group);Group III administered a topical application of AZA suspension; Group IV was given AZA-HBs; and Group V received the AZA-HBs/PVA/PVP-Cs-MN formulation. Data were expressed as Mean ± SD, n = 3. At the molecular level, the acne-like inflammatory model had elevated pro-inflammatory cytokines, activated TLR4/MYD88 signaling, and had a diminished antioxidant Nrf2/HO-1 axis. AZA-HBs/PVA/PVP-Cs-MNs treatment significantly reversed these effects. Increased levels of Nrf2 and HO-1 indicated the restoration of the body's internal antioxidant defense, and decreased levels of TLR4 and MYD88 indicated the stopping of the leading innate immune signaling which promotes cytokine production. Hence, the microneedle formulation appeared to reduce acne-related inflammation in a dual manner: stimulating the antioxidant defense through Nrf2/HO-1 pathway, and inhibiting the inflammation through the TLR4/MYD88 pathway. By and large, the microneedle components of this formulation are an improvement that support the emerging concept of microneedle systems as localized immune modulating and therapeutic systems within the cutaneous tissues (Ge et al., 2025a, 2025b; Zhang et al., 2021). The integration of immune microneedles into treatment strategies signifies the importance of the innate immune system in localized treatment and control. Furthermore, modern microneedles have become sophisticated systems that address the controlled, transdermal delivery of a variety of active substances beyond the traditional topical application. Thus, the AZA-HBs/PVA/PVP-Cs-MNs system presently brings these concepts to acne treatment by enhancing the delivery of AZA while simultaneously regulating inflammatory and antioxidant pathways (Ge et al., 2025b; Zhang et al., 2021). AZA nanocrystal hydrogel has also been studied as part of a dose-reduction strategy. Tomić et al. showed that a 10% AZA nanocrystal hydrogel achieved a treatment success rate of 36.51% after 8 weeks, compared with 30.37% for a conventional 20% AZA cream (Tomi'ctomi'c et al., 2021) (Tomi'ctomi'c et al., 2021). For AZA nanocrystal hydrogel, reductions in inflammatory and non-inflammatory lesions were 39.15% and 34.58%, respectively, compared to 33.76% and 27.96% for the 20% AZA cream. These results indicate that the ability to improve AZA delivery enables retention and/or enhancement of the therapeutic effect at lower AZA concentrations. The AZA-HBs/PVA/PVP-Cs-MNs system described in this study builds upon this concept by incorporating microneedle-assisted intradermal delivery and demonstrating multifunctional effects for anti-acne therapy such as antimicrobial, antibiofilm, and antioxidant effects coupled with reductions in inflammation and histological and molecular effects. Histopathology study Fig. 11 shows the effects of the assessed treatments in a rat ear acne model, along with corresponding histological analysis of the ear skin using the standard H&E method. The normal control group (GI) showed normal skin structure, including a normal epidermis (E), with no inflammation, edema, or vascular changes. The skin is in good condition. In contrast, the untreated diseased group (GII) showed advanced destructive changes, including acneiform skin changes. The epidermis showed significant hyperplasia with keratinocyte activation. Black arrows indicated the presence of inflammatory cells in the dermis and sub-epidermis. The red arrows indicate that inflammation increases blood vessel permeability and blood flow. The asterisk indicated that the tissue's inflammatory process was associated with swelling. All criteria indicated that the untreated group showed acute tissue inflammatory changes with significant destructive changes. The histological components changed significantly in the AZA suspension (GIII) treatment group relative to the diseased group. The epidermis was noted to collect as the segregation of epithelial cells was corrected. Inflammatory cells that accumulated and were distributed throughout the tissue were noted. This shows that AZA is anti-inflammatory. The AZA suspension is not as effective due to the lack of penetration in the deep dermis and local drug delivery. Microscopic pictures of HE-stained ear skin sections from the control normal group showing normal epidermis (E) with no signs of inflammation. Ear skin sections from untreated GII showing markedly thickened epidermis (E), besides deep inflammatory cells infiltration (black arrows), dilated blood vessels (red arrows), and edema (*). Ear skin sections from treated GIII showing moderately decreased thickness of epidermis (E) with few sub-epidermal inflammatory cells infiltration (black arrows). Ear skin sections from treated GIV showing moderately decreased epidermal thickening (E) with few sub-epidermal inflammatory cells infiltration (black arrows). Ear skin sections from treated GV showing normal epidermal thickening (E) with no signs of inflammation. (Low magnification ×100 bar 100 and high magnification x400 bar 50). (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.) Abbreviations: Group I: Normal Group; Group II: Positive; Control (Diseased Group); Group III administered a topical application of AZA suspension; Group IV was given AZA-HBs; and Group V received the AZA-HBs/PVA/PVP-Cs-MN formulation The AZA-HBs-treated group (GIV) showed a histological profile that was similar but slightly better. There was a slight decrease in epidermal thickness in this group, with even lower levels of inflammatory cell infiltration. As a result, AZA suspension has an adverse effect, suggesting that integrating AZA into the HBs system prolongs retention, distribution, and interaction with the subcutaneous tissue. Some inflammatory markers were resolved, suggesting that treatment was unsatisfactory. AZA-HBs/PVA/PVP-Cs-MN-treated group (GV) had the best histological improvement. The epidermis in this group was structurally similar to that of the control, with no signs of increased thickness, uneven inflammation distribution, vascular dilation, or edema. The microneedle formulation restored the negative effects of acne on skin architecture, demonstrating the best improvement results. The best improvement observed in the GV group is believed to be due to the microneedle system and its deep tissue formulation. The microneedles likely facilitate the penetration of AZA into the inflamed dermal layers by traversing the stratum corneum barrier. This improved the drug concentration at the site of pathology. The polymeric components, particularly Chitosan, may have contributed to anti-inflammatory and wound-healing effects, thereby facilitating further tissue repair (Fathy Elhabal et al., 2026a; Ndiaye et al., 2011). The complete resolution of histological aberrations in this cohort can be attributed to the synergistic effects of enhanced delivery, prolonged release, and the biomaterial's advantageous properties. The histological data significantly corroborate the biochemical and in vivo findings, indicating that the AZA-HBs/PVA/PVP-Cs-MN formulation is the superior therapy among those assessed. It successfully restored normal skin architecture, eliminated inflammatory infiltration, and reversed tissue damage, highlighting its potential as an advanced therapy method for acne management. Immunohistochemical (IHC) Examination of epidermal growth factor (EGF) Fig. 12 illustrates the expression of epidermal growth factor (EGF) in ear skin tissues across several experimental groups. This helps in understanding how the formulations studied support the healing process and tissue rejuvenation. These photomicrographs (Fig. 12a) help identify the presence of EGF in the substantia propria. Brown DAB staining shows where the staining occurs and helps identify the structures. The control group (GI) showed low EGF expression in the casein control, which is expected in standard casein products. Unlike the positive control (GII) and case lunged casein (sample and photomicrographs), which showed high expression of EGF. The increase in expression may be the body trying to stem the process of tissue wall breakdown and heal the tissue, and to open inflammation, which is why EGF expression may be high. Compared with the positive group in the control group, the casein-treated group (GIII) showed lower EGF expression; however, the positive group still showed high EGF expression. Indicating that the process is still leaking, and the body is healing; however, the body is still in great need of regeneration, and healing is not counted as normal (Henley et al., 2002; Rinne et al., 2025). The AZA-HBs (GIV) through the AZA group showed a promising reduction in EGF expression compared to AZA suspension. The noted reduction is negative healing. Thus, the positive healing, EGF, is a positive healing letter. This suggests an optimal healing process. Expression of inflammation through tissue restoration suggests that the inflammation is under control and that repair is prolonged. Controlled and sustained inflammation and repair are suggested through the distribution and intensity of the staining. Potential tissue overgrowth is indicated by staining intensity, which is described as the absence of loss of tissue integrity. The intensity of staining indicates that the sustained inflammation was controlled during the repair process through the regulation of tissue overgrowth. (a)photomicrograph for immunohistochemical staining of EGF in the substantia propria of ear skin tissues across experimental groups using the peroxidase–DAB method. Brown coloration indicates positive EGF expression. (b) Quantitative analysis of EGF immunostaining expressed as percentage area. Abbreviations: Group I: Normal Group; Group II: Positive; Control (Diseased Group);Group III administered a topical application of AZA suspension; Group IV was given AZA-HBs; and Group V received the AZA-HBs/PVA/PVP-Cs-MN formulation. Statistical significance is indicated as *p < 0.05, ***p < 0.001, and ****p < 0.0001 The quantitative analysis (Fig. 12b) corroborates these observations, showing the positive control group exhibited the greatest percentage area of EGF expression. The assessed groups showed a significant decrease in EGF expression inversely proportional to the level of treatment. Among the treatment groups, the formulation of AZA-HBs/PVA/PVP-Cs-MN showed the most pronounced effect, with a significant difference in EGF expression compared with the diseased control and the other treatment groups. Enhanced control of the tissue repair process is observed with the formulation compared to the others. Variances of EGF expression can also be understood in the context of inflammation and subsequent stages of wound healing. Analysis of the diseased group shows tissue loss associated with the body's, in this case, an overproduction of EGF, through inflammation and sustained tissue loss, which was the control gain. Administering appropriately modulated EGF to the formulation is beneficial, leading to sustained, controlled overexpression of inflammation and maintaining the established balance between tissue loss and gain. The AZA-HBs/PVA/PVP-Cs-MN formulation is superior as it achieved a more pronounced effect. All these mechanisms help reduce swelling and promote faster healing of a larger area of the affected area. The inclusion of Chitosan and the polymeric component can assist in healing the wound and regenerating the cells. The balance between the inflammatory and regenerative pathways provides an explanation for the enhanced histological and biochemical outcomes observed in this group. In general, the results from Fig. 12 show that acne-induced swelling increases EGF levels in the tissue, an attempt by the tissue to heal itself. However, effective therapy, especially the AZA-HBs/PVA/PVP-Cs-MN system, can restore EGF levels to normal, indicating that the wound has healed and balance has been restored to the skin. Conclusion This study shows that azelaic acid-loaded hyalubilosomes distributed within dissolving PVA/PVP-chitosan microneedles can successfully stimulate the development of a system that addresses the main delivery barriers to azelaic acid in acne treatment. The proposed system utilizes the benefits of hyalubilosomes, such as the vesicular encapsulation and hydration, combined with the sustained release and the ability of dissolving microneedles to penetrate the skin. Thus, AZA-HBs/PVA/PVP-Cs-MNs enhanced local drug delivery and achieved a multifunctional anti-acne effect through combined antimicrobial, antibiofilm, antioxidant, and anti-inflammatory effects. Based on these findings, the therapeutic advantage of the optimized system is presumed to extend beyond improved AZA permeation and to include an increase in local biological activity at the site of inflamed skin. The resolution of skin inflammation, together with the regulation of Nrf2/HO-1/MYD88 and histopathological markers, confirms the versatility of this system as a localized, minimally invasive, and non-antibiotic approach for the treatment of acne. This study, however, is not immune to some limitations. The biological study was undertaken in a preclinical rat ear acne-like inflammation model, which does not fully reflect the abnormality of acne vulgaris in humans. The long-term safety of repeated microneedle use, patient compliance, large-scale manufacturability, and clinical outcomes have not been evaluated here. Thus, further research is needed to assess repeated dermal safety and to study long-term stable storage, retention within skin follicles, potential irritation, and safety for therapeutic use in humans or in clinical settings. To provide a comprehensive evaluation of the feasibility of AZA-HBs/PVA/PVP-Cs-MNs microneedle patch system to provide an effective treatment system for acne utilizing intra-dermal delivery, future studies should develop a user optimized microneedle patch design, validate the proposed mechanisms of action for acne in models that present more clinical relevance, evaluate the safety profile for sustained repeated use, and prioritize studies that evaluate the trade-off between scale and the manufacturing process. AZA-HBs/PVA/PVP-Cs-MNs have the potential to be a safe and effective alternative to existing topical Azelaic Acid Formulations, however, this will only be confirmed following clinical studies. Credit authorship contribution statement Sammar Fathy Elhabal: Conceptualization, Methodology, and writing, supervision, investigation, reviewing & editing the manuscript. Fatma E. Hassan and Mohamed Fathi Mohamed Elrefai: Data curation, Formal analysis, and writing, reviewing & editing the manuscript, Nahla Sameh Tolba: Formal analysis, methodology, data curation, and writing, reviewing & editing the manuscript. Rania Mostafa Abd El Galil: Formal analysis, methodology, data curation and writing, reviewing & editing the manuscript. Suzan Awad AbdelGhany Morsy: Formal analysis, methodology, writing–original draft and writing, reviewing & editing the manuscript. Shady Allam and Amr M. Emam: Formal analysis, methodology, writing–original draft, and writing, reviewing & editing the manuscript. Hanaa Wanas: Formal analysis, data curation and writing, reviewing and editing the manuscript. Marian Sobhy Azer: Formal analysis, methodology, and writing, reviewing & editing the manuscript. Mona Mohamed Ahmed: Data curation and writing, reviewing and editing the manuscript. Hoda Ahmed Abdelmoneim:Formal analysis, methodology, and writing, reviewing & editing the manuscript. Marwa Fady: Data curation, Formal analysis and writing, reviewing & editing the manuscript. Ahmed Mohsen Elsaid Hamdan: Formal analysis, data curation, writing–original draft and writing, reviewing & editing the manuscript. All authors have read and agreed to the final version of the manuscript. Informed consent statement Not applicable. Institutional review board statement The animal study protocol was approved by the Research Ethics Committee, Faculty of Pharmacy, Cairo University (REC-FOPCU, protocol code PI 3998 and approval on 29 September 2025). Animal models are among the most important in vivo models for fundamental parameters, such as drug efficiency, safety, and toxicological studies, as pre-clinical data are necessary for translating into humans. The ARRIVE criteria for animal research were adhered to in using and handling the study's animals. Submission declaration and verification The authors declare that this manuscript has not been published or communicated for publication. elsewhere, either in part or in whole. Funding This research received no external funding. Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. Acknowledgments Not applicable. Contributor Information Sammar Fathy Elhabal, Email: Sammar.Fathy@pharm.mti.edu.eg. Ahmed Mohsen Elsaid Hamdan, Email: a_hamdan@ut.edu.sa. Data availability The data presented in this study are available on request from the corresponding authors. References Associated Data Data Availability Statement The data presented in this study are available on request from the corresponding authors.